A STUDY OF MULTIPARTICULATE DRUG DELIVERY SYSTEMS by XU MIN
  
 












A THESIS SUBMITTED FOR  
THE DEGREE OF DOCTOR OF PHILOSOPHY 
DEPARTMENT OF PHARMACY 









I hereby declare that this thesis is my original work and it has been written by 
me in its entirety. I have duly acknowledged all the sources of information 
which have been used in the thesis.  
 
 















First, I would like to extend my heartfelt gratitude to my supervisors Dr. Celine 
Valeria Liew and Associate Professor Paul Wan Sia Heng, for their continued 
dedication, guidance and supervision. Without them, this work would not have 
been possible. I would also like to express sincere appreciation to my thesis 
committee, Associate Professor Chan Lai Wah and Associate Professor T.R.R. 
Kurup, for their guidance of my research and thesis.  
 
My appreciation is also extended to the Head of Department, Associate 
Professor Christina Chai for use of the facilities at the Department of Pharmacy, 
National University of Singapore (NUS).  I am grateful to NUS for the 
administrative support and NUS Research Scholarship. 
 
I wish to acknowledge both Mrs. Teresa Ang and Ms. Wong Mei Yin for 
providing invaluable advice and technical assistance throughout my course of 
research. I also wish to thank my fellow GEANUSians, past and present, for 
their friendship, support and help during my four years PhD candidature. 
 
My deepest appreciation goes to my family and friends, whose understanding, 
love and faith encouraged me continually throughout this period. I wish to share 














TABLE OF CONTENTS 
TABLE OF CONTENTS……………………………….………………….III 
SUMMARY ................................................................................................ VIII 
PUBLICATIONS AND CONFERENCES ................................................... X 
LIST OF FIGURES ..................................................................................... XII 
LIST OF TABLES ......................................................................................XIV 
LIST OF SYMBOLS AND ABBREVIATIONS ......................................XVI 
Chapter 1. Introduction .................................................................................. 1 
1.1 Overview of coated multiparticulates .................................................... 4 
1.2 Coating of multiparticulates by fluidized bed process ........................... 5 
1.2.1 An overview of fluidized bed process ........................................... 6 
1.2.2 Fluidized bed processors with swirling airflow ............................. 9 
1.2.2.1 Precision Coater™ ................................................................. 9 
1.2.2.2 FlexStream™ fluidized bed processor ................................. 11 
1.2.3 Challenges in coating of multiparticulates by fluidized bed 
process...................................................................................................... 12 
1.2.4 Direct coating of drug particles for taste masking application .... 13 
1.3 Assessment of coat quality of multiparticulates .................................. 15 
1.3.1 Coat weight gain measurement .................................................... 15 
1.3.2 Color uniformity assay ................................................................. 16 
1.3.3 Coat thickness measurement ........................................................ 16 
1.3.4 In vitro dissolution study ............................................................. 17 
1.4 Multiparticulate drug delivery systems ................................................ 18 
1.4.1 Challenges in the design of MUPS tablets ................................... 20 
 iv 
 
1.4.2 Formulation related parameters on the extent of pellet coat 
damage ..................................................................................................... 23 
1.4.2.1 Polymeric coat ..................................................................... 23 
1.4.2.2 Pellet core properties............................................................ 26 
1.4.2.3 Cushioning agents ................................................................ 28 
1.4.2.4 Overcoat and undercoat ....................................................... 33 
1.4.2.5 Proportion of coated pellets ................................................. 35 
1.4.3 Process related parameters on the extent of pellet coat damage .. 36 
1.4.3.1 Compaction pressure ............................................................ 38 
1.4.3.2 Speed and time of compaction ............................................. 39 
1.4.4 Assessment of coat intergity of compacted pellets ...................... 43 
1.4.4.1 Model independent methods ................................................ 44 
1.4.4.2 Model-dependent methods ................................................... 47 
Chapter 2. Hypotheses and Objectives........................................................ 49 
Chapter 3. Materials and Methods .............................................................. 54 
3.1 Materials .............................................................................................. 55 
3.1.1 Materials for Study A................................................................... 55 
3.1.2 Materials for Study B ................................................................... 55 
3.1.3 Materials for Study C ................................................................... 56 
3.2 Methods................................................................................................ 57 
3.2.1 Study A - Coating of irregular-shaped small multiparticulates 
using the FS processor ............................................................................. 57 
3.2.1.1 Jet mill classification of primary drug particles ................... 57 
3.2.1.2 FS coating of primary drug particles ................................... 57 
 v 
 
3.2.1.3 Characterization of coated particles ..................................... 58 
3.2.2 Study B - Evaluation of the coat quality of extended release 
pellets by individual pellet dissolution methodology .............................. 62 
3.2.2.1 Rheological properties of powder blends ............................ 62 
3.2.2.2 Preparation of drug loaded pellets by extrusion-
spheronization ...................................................................................... 63 
3.2.2.3 Preparation of extended release pellets by fluidized bed 
coating………………………………………………………………..63 
3.2.2.4 Characterization of extended release pellets ........................ 64 
3.2.2.5 In vitro dissolution studies ................................................... 66 
3.2.2.6 Design of experiment ........................................................... 70 
3.2.2.7 Statistical analysis ................................................................ 71 
3.2.3 Study C. Part 1 - Development of cushioning agents with optimal 
stability and protective effect for compaction of coated pellets .............. 72 
3.2.3.1 Preparation of ML ................................................................ 72 
3.2.3.2 Preparation of spray dried ML-mannitol particles ............... 72 
3.2.3.3 Characterization of spray dried ML-mannitol particles ....... 74 
3.2.3.4 Preparation of coated pellets ................................................ 76 
3.2.3.5 Preparation of MUPS tablets containing EC-coated pellets 
and cushioning agents .......................................................................... 77 
3.2.3.6 Evaluation of MUPS tablets................................................. 77 
3.2.4 Study C. Part 2 - A mechanistic approach for analyzing the pellet 
coat damage caused by compaction in a rotary tablet press .................... 79 
3.2.4.1 Characterization of coated pellets ........................................ 79 
3.2.4.2 Determination of material true density ................................ 81 
 vi 
 
3.2.4.3 Evaluation of material compression behaviors .................... 81 
3.2.4.4 Preparation of MUPS tablets containing EC-coated pellets 
and sML_Man2_L ............................................................................... 82 
3.2.4.5 Evaluation of MUPS tablets................................................. 82 
3.2.4.6 Evaluation of EC-coated pellets in the MUPS tablet ........... 83 
Chapter 4. Results and Discussion ............................................................... 85 
4.1 Study A - Coating of irregular-shaped small particles using the FS 
processor ...................................................................................................... 86 
4.1.1 Physical characterization of coated particles ............................... 86 
4.1.2 Effect of swirling airflow on the coating efficiency of the FS 
processor .................................................................................................. 87 
4.1.3 Effect of particle size on coat uniformity .................................... 90 
4.1.4 Drug release properties and taste masking efficiency .................. 94 
4.1.5 Effect of coat weight gain on taste masking efficiency ............... 96 
4.1.6 Application of taste masked drug particles with small size for 
ODT platforms ......................................................................................... 98 
4.2 Study B - Evaluation of the coat quality of extended release pellets by 
individual pellet dissolution methodology ................................................... 99 
4.2.1 Physicochemical characteristics of extended release pellets ..... 100 
4.2.2 Drug release behavior of ensemble pellets in dissolution apparatus 
1 and 2 …………………………………………………………………100 
4.2.3 Optimizing operating parameters for dissolution testing of 
individual extended release pellet in the 400-DS dissolution apparatus 7 
by the DoE approach .............................................................................. 107 
 vii 
 
4.2.3.1 Influence of design variables on the average percentage drug 
release in each dip interval ................................................................. 108 
4.2.3.2 Influence of design variables on the standard deviation of 
average percentage drug release ........................................................ 110 
4.2.4 Optimization of dissolution parameters in the 400-DS dissolution 
apparatus 7 ............................................................................................. 111 
4.2.5 Comparison of release behaviors between the ensemble pellets 
and individual pellets ............................................................................. 113 
4.3 Study C. Part 1 - Development of cushioning agents with optimal 
stability and protective effect for compaction of coated pellets ................ 116 
4.3.1 Physical characterization of spray dried materials ..................... 117 
4.3.2 Stability of co-spray dried ML with mannitol upon storage at 
different RH conditions.......................................................................... 124 
4.3.3 Cushioning effects of co-spray dried ML with mannitol ........... 126 
4.4 Study C. Part 2 - A mechanistic approach for analyzing the pellet coat 
damage caused by compaction in a rotary tablet press .............................. 130 
4.4.1 Effect of dwell time and compaction pressure on the 
physicomechanical properties of MUPS tablets .................................... 131 
4.4.2 Compaction pressure and pellet coat damage ............................ 137 
4.4.3 Location of pellets in a MUPS tablet and extent of coat damage
 …………………………………………………………………139 
4.4.4 Pellet volume fraction and pellet coat damage .......................... 143 
Chapter 5. Conclusion ................................................................................ 148 





This research work looks into the different stages involved in the development 
of multiparticulate drug delivery systems for modifying drug release, including 
preparation of coated multiparticulates by the FlexStreamTM (FS) fluidized bed 
processor, assessment of pellet coat quality by dissolution apparatus 7, and 
compaction of coated pellets into multiple unit pellet system (MUPS) tablets.  
 
In the first part, the feasibility of coating irregular-shaped primary drug particles 
with wide size distribution was explored using the FS fluidized bed processor. 
After coating to 20%, w/w coat weight gain, the usable yield was 81% with 
minimal agglomeration (< 5%). Some aerodynamic modifications to the particle 
size and size distribution, shape and surface morphology were observed for the 
in-process samples with 5 and 10% coat weight gains, compared with the 
uncoated particles. Coated particles with 15%, w/w coat weight gain were found 
to have optimal taste masking efficiency, providing sufficient sealant properties 
at salivary pH with subsequent fast dissolution at gastric pH.  
 
The 400-DS dissolution apparatus 7 was employed to differentiate the 
individual coat quality of extended release pellets and to elaborate their 
underlying drug release mechanisms. A systematic design of experiment 
approach was used to optimize the operating parameters of the dissolution 
apparatus and mathematical models were successfully developed to describe the 
relationships between design variables and responses. The dip speed and dip 
interval of the reciprocating holder were critical parameters that affected the 
 ix 
 
drug release rate by changing the hydrodynamics and sink conditions in the 
dissolution medium. The drug release mechanism of the extended release pellets 
could be elaborated by the cumulative release profile obtained using the 
dissolution apparatus 7. Furthermore, the standard deviation of drug release rate 
was found to be a useful indicator of pellet coat quality.  
 
Mannitol was co-spray dried with micronized lactose in order to enhance the 
physicochemical properties of the resultant cushioning agents with protective 
effect for EC-coated pellets during compaction. MUPS tablet formulations 
containing EC-coated pellets and the spray dried cushioning agent 
sML_Man2_L were employed to investigate the formulation and process 
strategies for minimizing pellet coat damage during compaction. It was found 
that extending the dwell time from 10 to 40 millisecond during rotary 
compaction increased the mechanical strength of the resultant tablets by 62.8% 
without exacerbating the pellet coat damage sustained. Employment of 
compaction pressure lower than the pellet tensile strength was essential for 
ensuring pellet coat integrity. The location of the EC-coated pellets within the 
MUPS tablet could also affect the extent of coat damage, possibly due to the 
unequal force distribution in the compact during tableting. The formation of a 
continuous percolating network of cushioning agent is thus critical to limit the 
extent of pellet-pellet contacts and collisions between pellets and punch/die-
wall surfaces. A critical pellet volume fraction of 0.374, allowing the coated 
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Chapter 1. Introduction 
 2 
 
In the pharmaceutical industry, there is growing interest moving towards 
specialized drugs and formulations that are targeted to particular patient groups 
and ultimately, towards an individual patient and his specific therapeutic needs. 
(Van Arnum, 2014). Approaches to achieve individual therapy may be based on 
dose adjustment, drug combination or different delivery kinetics. However, to 
date, there is still an unmet need for appropriate drug delivery systems that 
provide greater flexibility and ease in dose adjustment and/or are designed with 
special features to suit the requirements of specific patient groups (Wening and 
Breitkreutz, 2011).  
 
The modified release dosage form is designed to modulate the apparent 
absorption and/or alter the site of drug release with the purpose of improving 
therapeutic efficacy and reducing adverse side effects. Extended, delayed or 
site-specific release of the active pharmaceutical ingredients (APIs) are 
commonly seen modes to achieve modified release drug delivery (Martinez et 
al., 2010). The modified release dosage form has been shown to exhibit a 
number of advantages over its immediate release counterpart. For example, 
extended release drug products release the API over a prolonged period of time 
and allow at least a twofold decrease in dosing frequency (Varum et al., 2010), 
as shown in Figure 1 (A). Such extended release of drug could maintain the drug 
plasma concentration at therapeutic level for longer periods. Hence, the 
resultant therapeutic ‘steady-state’ plasma concentration of the drug reduces the 
incidence and severity of dose-related systemic and local adverse side effects 
such as nausea, vomiting and ulcers from local irritation (Follonier et al., 1995). 
Delayed release products can release the drug at a time other than promptly after 
 3 
 
administration as shown in Figure 1 (B). The gastro-resistant dosage form is one 
example of delayed release dosage form, which holds the drug in the dosage 
form while in the acid environment of the stomach and releases the drug in the 
higher pH environment of the small intestine. This is particularly useful in the 
case of acid-sensitive drug as the drug is protected from the acidic environment 



















































Figure 1. Schematic diagram of modified release profiles: (A) extended release  
and (B) delayed release.  
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To date, oral drug delivery is still the most important and most frequently used 
drug delivery route. Therefore, suitable oral drug delivery systems with options 
for modifying drug release are highly desirable. Coated multiparticulates 
possess many benefits and have seen increasing popularity in a variety of 
modified release applications (Chang and Robinson, 1990). An overview of 
coated multiparticulates and their application in drug delivery are provided in 
the following sections.  
 
1.1 Overview of coated multiparticulates 
Multiparticulates are small discrete particulates (e.g. pellets, granules, 
minitablets, drug crystals) that are collated into one dosage entity to form a 
multiple-unit system such as a capsule or tablet (Porter, 2013). Spherical shape 
multiparticulates, or pellets, are most commonly used as they possess spherical 
shape and narrow size distribution, free flowability and ability to pack 
uniformly, and minimum surface to volume ratio with a consistent and definable 
surface for drug release. Multiparticulates have been shown to have a number 
of therapeutic advantages over the conventional single unit dosage forms such 
as tablets (Bechgaard and Nielsen, 1978; Ghebre-Selassie, 1994). For instance, 
the coated tablets were reported to undergo less predictable gastrointestinal (GI) 
transit times and may potentially lodge in restrictions within the GI tract, which 
could lead to variable drug absorption and cause damage to the gastric mucosa 
if the drug is irritant. In contrast, the small-size multiparticulates (typically 0.5-
2.0 mm) distribute readily over a large surface area in the GI tract, which helps 
to maximize drug absorption and improves bioavailability. It has been 
established that particles with sizes less than 2.0 mm pass through the 
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constricted pyloric sphincter even during the gastric phase of the digestion 
process (Davis et al., 1984; Abrahamsson et al., 1996) and therefore, the fast GI 
transit time of multiparticulates minimizes the risk of local entrapment and 
avoids drug degradation and mucosal irritation. Moreover, as the total dosage 
unit is divided into a large number of discrete small multiparticulates, dose 
dumping due to failure of the film coat would not lead to failure of the whole 
dosage unit.  
 
1.2 Coating of multiparticulates by fluidized bed process 
Multiparticulates are commonly coated for various reasons, ranging from 
aesthetic purposes to therapeutic necessity. For example, color coats could be 
used to enhance product appearance and facilitate the identification of different 
dosage strengths and drugs, thereby preventing mistakes in drug administration. 
Multiparticulates with unpleasant taste or odor are often coated with a taste 
masking barrier to prevent leaching of materials from the cores and to improve 
patient acceptance of the product. More importantly, multiparticulates are 
commonly coated using film coatings with rate controlling properties for 
extended and/or delayed drug delivery (Chang and Robinson, 1990). Coated 
multiparticulates could be prepared via various processes, including fluidized 
bed coating, complex coacervation, interfacial complexation, interfacial 
polymerization, compression coating, spray drying and spray congealing. 
Among these methods, the fluidized bed coating process is used in preference, 
owing to its ability to form high quality, multilayer coatings and its capability 




1.2.1 An overview of fluidized bed process 
The fluidized bed process has been commonly employed for coating 
multiparticulates since its introduction into the pharmaceutical industry by 
Wurster in 1959 (Wurster, 1959). In a fluidized bed processor, a bed of particles 
is suspended to behave like a liquid by the passage of a fluidizing fluid, typically 
air, at a flow rate above a certain critical value (minimum fluidization velocity) 
and this phenomenon of a fluid-like bed is termed as fluidization (Dixit and 
Puthli, 2009). Fluidized bed processors are generally classified into three types, 
namely the top-spray, bottom-spray and tangential-spray processors (Jones and 
Percel, 1994), depending on the position of the spray nozzle(s). Schematic 
diagrams of these three types of fluidized bed processors are given in Figure 2. 
The orientation of the spray nozzle determines not only the spray pattern of the 
liquid, but also how the spray droplets impinge and spread on the particles. The 
following sections describe different categories of fluidized bed processors and 
discuss the effects of equipment designs on their performance and efficiency 
when employed for coating of multiparticulates.  
 
The top-spray fluidized bed processor, as depicted in Figure 2 (A), was first 
introduced for granulation in the 1960s (Banks and Aulton, 1991). The spray 
nozzle is positioned above the powder bed and faces downward, spraying 
counter-currently to the fluidization airflow. Due to the longer distance between 
the spray nozzle and product bed, it has the highest incidence of spray drying of 
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Figure 2. Schematic diagrams of (A) top-spray; (B) bottom-spray and (C) 
tangential-spray fluidized bed processors. Dark arrows in the diagrams indicate 




The counter-current direction of the spray droplets against the fluidizing air also 
promotes spray drying. Another disadvantage of is that there are no distinct 
coating and drying zones in the top-spray processor, leading to a higher 
tendency for agglomeration and intense attrition. Hence, the top-spray processor 
is a less effective technology for coating multiparticulates (Felton and Porter, 
2013). 
 
The bottom-spray processor, also referred to as the Wurster processor, is the 
most commonly used method for coating multiparticulates in the 
pharmaceutical industry. The Wurster coater is designed with the spray nozzle 
located at the bottom of the product chamber (Figure 2 (B)). A partition column 
is inserted above the nozzle with the perforated area directly underneath, where 
a high velocity upward air stream into the column produces a lower pressure 
zone. Due to the pressure difference, the substrate particles are sucked into the 
partition column via the partition gap and coated by the co-current atomized 
coating liquid spray as the particles travel up the column. After exiting at the 
top of the column, the particles decelerate and settle onto the annular staging 
bed. This particle movement pattern in the Wurster processor is typically 
referred to as a fountain-like cyclic flow. As the distance between the spray 
nozzle and particles is very close and the air flow delivers particles through the 
partition column at a relatively slow rate, the particles are liable to formation of 
liquid bridges between each other and thus have a higher chance of 
agglomeration (Ichikawa and Fukumori, 1999). With lower airflow, particle 




The tangential-spray fluidized bed processor, also known as the rotary processor, 
makes use of a rotating frictional disc to move substrates in a circular manner 
while the motionless outer rim is perforated to allow fluidizing air to pass 
through, as shown in Figure 2 (C). The spray nozzle is located at the side wall 
and the spray path is in a tangential direction to the rotating plate. Typically, the 
powder bed exhibits a rope-like movement due to the combined effects of the 
centrifugal force from the rotating frictional plate, the uplifting force from the 
gap air and the gravitational force. The tangential-spray fluidized bed processor 
has been shown to cause less spray drying effect compared with the top-spray 
processor. This is attributed to the rapid tumbling motion and high particle 
velocity during the process. 
  
1.2.2 Fluidized bed processors with swirling airflow 
Incorporation of swirling airflow by modifying air flow pattern into the partition 
column has been found to improve coating performance (Dreu et al., 2012). 
Swirling airflow enables a rotational motion about the central axis and it has 
been shown in various studies to improve heat transfer and increase drying 
efficiency during the fluidized bed coating process when compared with non-
swirling airflow. (Özbey and Söylemez, 2005; Kaewklum and Kuprianov, 2010; 
Ortega-Casanova, 2012). Detailed discussion on two designs of fluidized bed 
processors with swirling airflow are provided in the following sections.   
 
1.2.2.1 Precision Coater™  
The Precision Coater™ is a modified bottom-spray fluidized bed processor 
(Walter, 1998), which uses a highly controlled airflow pattern to improve the 
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A swirl accelerator under the air distribution plate swirls and accelerates the 
fluidizing air to impart spin and high velocity to the substrate particles as they 
Non-sifting gill plate 
Swirling airflow 
Spray nozzle 
Figure 3. Schematic diagrams of the (A) Precision Coater™ and (B) FlexStreamTM 





transit through the partition column (Mehta, 1997). The air accelerator insert, 
with a narrower opening at the top, is placed in the central part of the air 
distribution plate. The swirling airflow used in the Precision Coater™ has been 
shown to enhance the deposition and drying of spray coating droplets with 
increased coating efficiency and better coat quality (Heng et al., 2006). 
However, the Precision Coater™ does not take full advantage of the swirling 
airflow as the swirling airflow is limited within the partition column of the 
processor. 
 
1.2.2.2 FlexStream™ fluidized bed processor 
The findings on effect of swirling airflow in the Precision Coater™, albeit 
limited, indicated the potential of swirling airflow in improving the performance 
of the fluidized bed coating process. The FlexStream™ fluidized bed (FS) 
processor is a modified tangential-spray fluidized bed processor with swirling 
airflow generated by the patented non-sifting gill plate. As can be seen in the 
schematic diagram of the FS processor in Figure 3 (B), the airflow in the product 
chamber swirls within the whole product chamber in contrast to a localized 
region within the partition column in the Precision Coater™. Another important 
feature of the FS processor is the low pressure side-spray enveloping airflow, 
which is extracted from the inlet plenum and conditioned the same way as the 
fluidization airflow. This airflow could extend the reach of the liquid spray to 
deeper regions of the particle bed and create a particle-free zone around the 
spray nozzle, and hence prevent local over-wetting of the core particles by the 
liquid spray. A recent study (Wong et al., 2012) reported on the optimization of 
FS processor for fast speed granulation by applying the design of experiment 
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(DoE) approach and examined the effects of airflow rate, atomizing air pressure, 
and distance between spray nozzle and powder bed on the resultant granule 
properties. In this granulation study, the FS processor was found to be stable 
and efficient at a high binder spray rate and produced granules with narrow size 
distribution, desirable physical characteristics and low percentage of fines. It 
should also be noted that the FS processor allows linear scale-up capability with 
the addition of multiple circumferential nozzles in larger units. 
 
1.2.3 Challenges in coating of multiparticulates by fluidized bed process 
The technological and therapeutic advantages of coated multiparticulates are 
associated with their multiple-unit nature and small particle size. Nevertheless, 
to date, successful coating of multiparticulates using the conventional fluidized 
bed process generally requires spherical pellets larger than 710 μm and with 
narrow size distribution (Hutchings and Sakr, 1994; Lorck et al., 1997; Wang 
et al., 2010). This is mainly attributed to the superior properties of pellets, such 
as minimum surface area to volume ratio, smooth surface, good flowability and 
ability to withstand mechanical stresses. Success at coating much smaller 
multiparticulates, especially those that are irregular in shape such as granules 
and drug crystals, has not been as encouraging (Jones and Percel, 1994; Tang et 
al., 2008). These substrate particles are more challenging to coat using the 
fluidized bed process due to various reasons. The high surface area to volume 
ratio, cohesive nature and poor flowability of small particles increased risks of 
over-wetting and agglomeration during the coating operation. In addition, the 
strong inter-particle adhesion forces between smaller particles led to generally 
poor fluidization, which compromised their propensity to be coated as single 
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particles as the more likely consequence was agglomeration (Jono et al., 2000; 
Watano et al., 2004; Kondo et al., 2013; Ishida et al., 2014). Watano et al. (2004) 
achieved coating of fine corn starch powders with an aqueous solution of 
hydroxypropylcellulose using a rotating fluidized bed coater. However, a 
specially designed coater was required for the coating operation and the liquid 
spray rate employed (approximately 0.75 g/min) was extremely low. Such low 
process efficiency may potentially limit the application of this coating process 
in industrial manufacturing, as it is preferable that a large volume of coating 
liquid be delivered within the shortest possible time. Ishida et al. (2014) reported 
the successful coating of porous spherical silica beads with median particle size 
of 100 µm in a spouted bed coater. In their study, although suppression of 
particle aggregation and shortening of coating time were achieved, the coating 
batch size was only 100 g and the conclusions drawn were limited to a 
laboratory scale processor.  
 
1.2.4 Direct coating of drug particles for taste masking application 
An orally disintegrating tablet (ODT), also known as rapidly disintegrating, 
orodispersible, fast-melting or mouth-dissolving tablet, is a solid dosage form 
that disintegrates or dissolves in the mouth rapidly within a few seconds upon 
contact with saliva (Al-Khattawi and Mohammed, 2013). ODTs can be 
consumed without the need for water and could be particularly useful for 
children, elderly patients and those who have difficulties in swallowing 
(Shahiwala, 2011). ODTs are well recognized by the European Medicines 
Agency’s (EMA) Committee for Medicinal Product for Human Use (CHMP) as 
a promising platform for pediatric drug delivery (EMA, 2013). During the 
 14 
 
development of a pediatric oral formulation, the critical factors to ensure 
children’s adherence to the therapeutic regimen are an acceptable taste and ease 
of swallowing. Although sweeteners or flavoring agents could be added to the 
formulation to alter the unpleasant taste of APIs, frequent and/or large doses of 
sweeteners should be avoided, especially in medicines for treating chronic 
diseases. A neutral taste is generally favored. This is because with repeated and 
long-term use, patients may find formulations with a strong flavor no longer 
palatable. Moreover, pediatric preparations should not have a very candy-like 
taste and be too appealing to children so as to reduce risk of accidental 
consumption and poisoning (EMA, 2006). Another limitation with the use of 
sweeteners or flavoring agents is that an extremely bitter drug may not be 
sufficiently taste masked with sweeteners or flavoring agents alone. Hence, taste 
masking the API by coating the drug particles with a suitable film coat to give 
a neutral taste is preferred as the applied coating can efficiently suppress the 
dissolution of the API while in the mouth.  
 
A number of patents and studies have shown the potential of taste masked 
particles to be compressed into ODTs, which could be conveniently achieved 
with conventional tableting equipment (Douroumis, 2011). The preferred size 
range of particles to be formulated into an ODT is less than 500 µm to avoid a 
gritty feeling in the mouth (Kondo et al., 2013). The small size of taste masked 
particles also facilitated tableting due to the greater surface area for inter-
particle bonding and the resultant tablets usually exhibited higher tensile 
strength (Jono et al., 2000). There is a growing interest in the coating of primary 
drug particles for taste masking application. This one-step approach is efficient, 
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cost-effective and produces taste masked particles with a high drug content 
(Sohi et al., 2004). However, to date, direct coating of irregular-shaped drug 
particles with sizes less than 500 µm using fluidized bed processors has not been 
fully explored due to the challenges associated with increased risk of over-
wetting and agglomeration. Hence, it is necessary to evaluate the feasibility of 
employing the FS processor to overcome these challenges in direct coating of 
primary drug particles with irregular shape and wide size distribution.   
 
1.3 Assessment of coat quality of multiparticulates 
The uniform thickness and integrity of the deposited coat are critical to the 
functionality of multiparticulates designed for modifying drug release. However, 
coating defects such as blisters, flaking, cracks and pin holes usually result in 
premature exposure of the core content to the external media, impeding the 
modification of drug release from multiparticulates. To date, various types of 
techniques have been developed to examine the uniformity and quality of 
multiparticulate coatings either qualitatively or quantitatively. These techniques 
differ in their accuracy, efficiency and applicability. In this section, the 
principles of different characterization techniques to assess coat quality of 
multiparticulates are evaluated and their potential drawbacks discussed, in order 
to highlight the rationale for the development of a new method for coat quality 
assessment.  
 
1.3.1 Coat weight gain measurement 
Coat weight gain, which is often expressed as the percentage of the coating 
polymer applied onto the pellets, is the traditionally used approach to infer the 
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coat thickness of multiparticulates (Ringqvist et al., 2003). However, the weight 
gain measurement is an estimated value and does not consider the 
physicochemical properties of the multiparticulate coat (Ho et al., 2009). 
Therefore, it is non-specific as an approach for the quantification of 
multiparticulate coat quality.  
 
1.3.2 Color uniformity assay 
As the coat weight gain measurement only measures the total amount of coating 
on the multiparticulates, this approach does not provide information on the 
uniformity of the applied coating. Thus, spot color measurement using the 
tristimulus colorimeter was employed to evaluate the color coat distribution on 
multiparticulate surface and to study the influence of process factors on the 
coating efficiency of the Wurster fluidized bed processor (Chan et al., 2001). In 
addition, tristimulus color assessment is useful for routine quality control and 
color stability study of coated multiparticulates (Turi et al., 1972). Nonetheless, 
there are limitations to the application of these colorimetric techniques as they 
require the multiparticulates to be color coated. 
 
1.3.3 Coat thickness measurement 
Besides quantifying color uniformity of coated multiparticulates, visual 
observations with light and scanning electron microscopy (SEM) could be used 
to measure the coat thickness of individual multiparticulates. However, such 
microscopy techniques are restricted to the sample surface properties and there 
are technical problems such as the difficulty in cross-sectioning spherical 
particles (Wesdyk et al., 1990). Confocal laser scanning microscopy has been 
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introduced as a non-destructive technique for imaging film-core interface and 
quantifying the coat quality of individual thinly-coated multiparticulates by 
measuring their coating thickness (Depypere et al., 2009). Other analytical 
techniques including atomic force microscopy (Ringqvist et al., 2003), nuclear 
magnetic resonance spectroscopy, energy dispersive x-ray imaging (Ensslin et 
al., 2008), terahertz imaging (Haaser et al., 2013), electron paramagnetic 
resonance spectroscopy (Ensslin et al., 2009), and fluorescence microscopy 
(Andersson et al., 2000) were also employed to investigate the physical 
characteristics of film coating. In order to estimate the coat thickness, 
assumption of the coated multiparticulate as a perfect sphere is often required. 
However, multiparticulates such as granules or crystals are often less than 
perfect spheres and may present as elongated, elliptical or even rod-like 
particulates. Furthermore, although these microscopy and spectroscopy 
techniques are able to indicate multiparticulate coat uniformity by measuring 
the coat thickness, there may not be a direct relationship between these physical 
coat properties and the drug release behavior of the coated multiparticulates.  
 
1.3.4 In vitro dissolution study 
With regard to coated multiparticulates for modifying drug release, in vitro 
dissolution tests are often carried out using compendial dissolution apparatus to 
ensure coat quality and release performance (Zahirul and Khan, 1996). This 
method could establish a direct relationship between the dissolution properties 
of extended release multiparticulates and their coat qualities. However, the 
dissolution profile of a multiparticulate drug delivery system obtained using the 
United States Pharmacopeia (USP) dissolution apparatus 1 or 2 is a summation 
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of the drug release from all the multiparticulates. There is little information on 
the release performance of individual multiparticulates from the overall 
dissolution profile (Hoffman et al., 1986). Regarding the coating operation, the 
drug release behavior of different multiparticulates from the same coating batch 
are known to vary to a great extent (Borgquist et al., 2004). Therefore, the coat 
quality and drug release behavior of one single multiparticulate cannot be 
accurately determined using these conventional dissolution methods.  
 
The reciprocating holder dissolution apparatus, designed in compliance with all 
the compendial requirements of USP apparatus 7, is a small-volume dissolution 
testing system for non-disintegrating and extended release dosage forms (Crist, 
2009). It was found to be suitable for release testing of slowly releasing actives 
from implants, medical devices such as drug eluting stents and small 
transdermal patches (Zhou et al., 2007). This apparatus uses a reciprocating 
motion to dip a dosage form in the dissolution medium at programmed time 
intervals. Extended release pellets with water-insoluble polymer coats can 
remain physically unaffected in aqueous medium for a considerably long period 
and as the drug content in an individual pellet is rather low, the small-volume 
dissolution system of apparatus 7 might be useful for determining the release 
characteristics of individual extended release pellets. 
 
1.4 Multiparticulate drug delivery systems 
To date, multiparticulates are most commonly filled into hard gelatin capsules 
as final dosage forms. Due to several disadvantages of the capsule dosage form, 
there is growing interest in the compaction of coated multiparticulates into 
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tablets. First, the fact that the cap and body of a capsule can be pulled apart may 
potentially lead to tampering concerns. If the capsule is functional, this could 
further change the therapeutic effect of the medicine. Capsule shell materials 
from animal sources, such as gelatin, may not be acceptable to vegetarians and 
certain religious groups and could compromise the patients’ compliance to the 
medication. In addition, the output rate of an industrial-scale capsule filling 
machine varies between 3,000 to 150,000 capsules per hour (Jones, 2013). This 
is much lower than the efficiency of tablet compression where the production 
rate of a rotary tablet press can reach over 600,000 tablets per hour (Alderborn, 
2013). 
 
MUPS tablet is defined as a multiple-unit pellet system in the form of a tablet, 
intended to disintegrate into individual pellets upon oral administration (Abdul 
et al., 2010). The first MUPS tablet, Omeprazole MUPS®, was introduced into 
the market in 1994 to optimize delivery of omeprazole to the site of absorption 
in the small intestine (Aubert et al., 2011). The concept of MUPS tablet may be 
extended to ODTs containing coated particles. For example, compaction of 
various types of multiparticulates, such as the drug-containing coated 
microparticles (Kurimoto et al., 2004) and fine granules with an enteric coating 
layer (Shimizu et al., 2002), into ODTs have been reported.  
 
To date, although MUPS tablets have shown potential as an efficient drug 
delivery system, multiparticulate drug delivery systems in the form of coated 
pellets filled in capsules are still more common due to a number of challenges 
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faced during compaction of coated pellets, which will be addressed in the 
following sections.   
 
1.4.1 Challenges in the design of MUPS tablets 
The most common challenge faced in compaction of coated pellets is the 
structural damage to the functional pellet coat caused by the compaction force 
needed to form the tablet. As a result, a drastic change in the drug release 
properties of the coated pellets was often observed after compaction (Bansal et 
al., 1993; Bodmeier and Paeratakul, 1994a; Bodmeier, 1997; Dashevsky et al., 
2004). Besides coat damage, coated pellets might also fuse together into a non-
disintegrating matrix tablet under compaction force (Dashevsky et al., 2004). 
Moreover, due to differences in their shape, size and flow properties, 
segregation of the coated pellets and compaction fillers may occur during 
mixing and die filling (Lundqvist et al., 1998; Wagner et al., 1999). These 
challenges have been addressed by a number of studies on compaction of coated 
pellets using various formulation and process approaches (Torrado and 
Augsburger, 1994; Wagner et al., 2000b; Vergote et al., 2002; Picker, 2004; 
Schmid and Picker-Freyer, 2009; Hosseini et al., 2013). However, some 
conflicting findings have been reported and strategies that can be employed to 
successfully overcome these challenges are still rare (Bodmeier, 1997). A 
schematic diagram demonstrating the compaction process of coated pellets and 
the related factors which pose effects on the pellet coat damage are shown in 
Figure 4. The formulation and process related parameters that were found to 
influence the extent of pellet coat damage are summarized in Table 1. Among 
these factors, the effects of cushioning agent, compaction pressure and 
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proportion of coated pellets with cushioning agents on the extent of pellet coat 
damage were investigated in Study C.      
          
          
          
          
          
  
Figure 4. Schematic diagram depicting the compaction process of coated pellets 
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Table 1. Summary of formulation and process related parameters that influence 
the extent of pellet coat damage.        
  : Denotes decrease in level of coat damage when parameter is increased 
  : Denotes increase in level of coat damage when parameter is increased 
-: Denotes insignificant change in level of coat damage when parameter is increased 











Bansal et al., 1993; Sarisuta and 
Punpreuk, 1994; Bodmeier, 1997; 
Lehmann, 1994; Lundqvist et al., 1998; 
Maganti and Çelik, 1994; Vergote et al., 
2002; Dashevsky et al., 2004; Debunne et 
al., 2004; Cantor et al., 2009; Rujivipat 
and Bodmeier, 2012 
Coat thickness  
Beckert et al., 1996; Lundqvist et al., 






Altaf et al., 1998, 1999; Haslam et al., 
1998; El-Gazayerly et al., 2004; Chambin 
et al., 2005; Hosseini et al., 2013;  
Pellet core 
Size       /  
Bechard and Leroux, 1992; Haslam et al., 
1998; Ragnarsson et al., 1987 
Porosity  Tunón et al., 2003a;  
Deformability  Tunón et al., 2003a; Mendyk et al., 2010 
Tensile 
strength 




Picker, 2004; Schmid and Picker-Freyer, 




 Picker, 2004; Schmid and Picker-Freyer, 
2009 
Particle size     / Haslam et al., 1998; Yao et al., 1998 
% reduction in 
volume 
 Yuasa et al., 2001 
Proportion of 
coated pellets / 
fillers 
    /    / - 
Torrado and Augsburger, 1994; Beckert 
et al., 1996; Lundqvist et al., 1998; 
Wagner et al., 1999; Wagner et al., 2000a; 
Vergote et al., 2002; Dashevsky et al., 
2004; Mehta et al., 2012  
Process 
parameters 
Speed of rotary 
tablet press 
       - Wagner et al., 2000b 
Compaction 
pressure 
      /    / - 
Bansal et al., 1993; Torrado and 
Augsburger, 1994; Lundqvist et al., 
1998; Dashevsky et al., 2004 
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1.4.2 Formulation related parameters on the extent of pellet coat damage 
1.4.2.1 Polymeric coat 
Polymeric coats are often employed for modifying drug release from 
multiparticulates. Based on their solubility in water, these polymers can be 
classified into three broad groups. The majority of acrylic polymers are 
marketed under the trade names Kollicoat® or Eudragit®. The major cellulosic 
polymer used for extended release is ethyl cellulose (EC), under the trade names 
of Aquacoat® and Surelease®. 
 
Water insoluble polymers (such as EC, polymethacrylate copolymers with 
quaternary ammonia groups and polyvinyl acetate) are typically used to 
formulate membrane-controlled drug release systems and the extended release 
of drug is controlled by diffusion through the polymeric coat. Among these 
polymers, EC is a highly suitable polymer for coating multiparticulates for 
extended drug release due to its safety, good film forming properties and 
availability in the form of aqueous dispersions. With a high glass transition of 
120 °C, the EC based film coats are usually very hard and brittle, and thus need 
a plasticizer to soften and improve its flexibility (Harris and Ghebre-Sellassie, 
2008). It has been shown that the Aquacoat® film, prepared by film casting 
from plasticized pseudolatexes, was very brittle and low in mechanical strength, 
regardless of the types of plasticizers used and method of curing (Bodmeier and 
Paeratakul, 1994b). As a result, the EC film coats are prone to be ruptured by 
the compaction force during tableting and the extended drug release function is 
usually compromised after compaction. Due to the low flexibility of EC, the 
thickness of the film coats was observed to have minor effect on the extent of 
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coat damage. Maganti and Çelik (1994) prepared Surelease® coated pellets with 
10, 15 and 20%, w/w coating levels to investigate their compaction 
characteristics. Although increasing coating levels of Surelease® changed the 
deformation behavior of the uncoated pellets from brittle and elastic to plasto-
elastic, the resultant MUPS tablets exhibited lower tensile strength and higher 
elastic recovery upon ejection. Moreover, the pellets with all levels of coat 
thickness were found to lose their coat integrity after being compacted, 
regardless of the compaction pressure. This universal coat damage was 
attributed to pellet fragmentation and crack formation on the EC film coat.   
 
Polymethacrylate based polymers exhibit pH-dependent solubility, which is 
determined by the cationic or anionic functional groups in the polymer side 
chain. In response to the physiological pH profiles of humans, these polymers 
enable gastrointestinal targeting to either the stomach, small intestine or colon. 
For instance, the cationic Eudragit® E types are soluble in acidic fluid whereas 
the anionic Eudragit® L, S and FS types dissolve in neutral or alkaline fluids. 
Insoluble Eudragit® RL/RS types provide different permeability of moisture, 
due to the presence of hydrophilic quaternary ammonium groups as 
hydrochlorides. The other types of insoluble coatings such as Eudragit® 
NE/NM are neutral copolymers with no functional groups (Skalsky and Petereit, 
2008). When compared to the EC film coats, these film coats prepared from the 
polymethacrylate based polymers are usually more flexible and resilient to the 
damaging effect of compaction force. Among the different polymethacrylates, 
Eudragit® E, Eudragit® FS 30 D, Eudragit® NE 30 D, and Eudragit® NM 30 
D are suitable film coats for coated pellets meant for compaction owing to their 
 25 
 
sufficient elasticity to deform during compaction (Wagner et al., 2000a; 
Debunne et al., 2004). However, pellets coated with the anionic 
polymethacrylates such as Eudragit® L 30D are more prone to be damaged by 
compaction as these polymers are more brittle. Hence, the addition of 
plasticizers or mixing with soft Eudragit® NE 30 D is necessary to achieve the 
required elasticity (Lehmann et al., 1994; Shimizu et al., 2003a; Shimizu et al., 
2003b; Shimizu et al., 2003c). Although plasticized polymethacrylates provide 
sufficient flexibility to deform under compaction force, the drug release 
properties of the resultant MUPS tablets may still be compromised due to the 
fusion of the coated pellets. For instance, the compression behavior of 
acetylsalicylic acid (ASA) crystals, ASA pellets and coated ASA pellets (with 
dibutylphthalate plasticized Eudragit® RS) was investigated by López-
Rodríguez et al. In their study, the coated ASA pellets were observed to fuse 
together during compaction and led to formation of matrix tablets. In order to 
prevent pellet-pellet contact, the addition of microcrystalline cellulose (MCC) 
in the tablet formulation at a concentration higher than 15%, w/w was necessary 
(López-Rodríguez et al., 1993).  The film tackiness of acrylic polymers was also 
observed during storage, especially when stored at conditions with elevated 
temperatures and humidities. An agglomerated cake formed after pellets coated 
with Eudragit L 30 D-55 and FS 30 D (ratio 6:4) were stored for 7 months at 
40 °C and 75% relative humidity (RH) (Debunne et al., 2002). Separation of 
these agglomerated pellets led to damage of the coating and faster drug release. 
 
As discussed above, the flexibility of the film coat and its ability to 
accommodate deformation during compaction are critical to avoid the 
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deleterious effects arising from compaction. In addition, it was generally 
accepted that the structure of both the pellet core and the coating are inter-
related. Therefore, as a rule, film coatings and pellet cores should have similar 
mechanical properties.  
 
1.4.2.2 Pellet core properties 
Enteric coated pellets with two different crushing strengths were prepared and 
compacted into fast disintegrating tablets (Beckert et al., 1996). In this study, 
the pellet coat damage was primarily attributed to the compaction pressure that 
caused building up of high stress at localized points of pellet-pellet contact. As 
a result, the pellet film coating was ruptured regardless of the types of 
compaction excipients used. It was found that with a brittle film coating, the 
harder pellets were better able to withstand compaction force, preventing the 
film coat from rupturing. However, the relationship between compaction 
pressure and the extent of pellet coat damage was not quantified in the study. 
Tunón et al. later found that the use of porous and deformable pellets was more 
advantageous in preserving the coat integrity when comparing between the hard 
and non-porous pellets (Tunón et al., 2003). These authors postulated that the 
deformation of the pellets had facilitated transmission of compaction force to 
spread out over a large area of contact, and thus resulted in less damage to the 
film coating. Nonetheless, due to a number of confounding factors observed in 
the study, the slower drug release from coated pellets with more porous cores 
might be due to densification of the film coating, which deformed together with 
the pellet core. In addition, coated pellets with low porosity were prone to more 
contact with the punch and die surface and thus sustained greater coat damage.  
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A subsequent study by Tunón et al. (2003b) proposed a hypothesis stating that 
the final structure of the film coating might be altered in two opposing ways 
when the coated pellets were compacted, i.e., the thinning and stretching of the 
coating due to pellet core deformation, as well as the compression and 
thickening of the coating caused by densification of the pellet core. The former 
accelerated while the latter prolonged drug release rate.  
 
Besides porosity and deformability of the pellet core, the size of pellet core also 
contributes to the failure of coat function during compaction. EC coated pellets 
with smaller size were observed to have a greater extent of coat damage 
(Bechard and Leroux, 1992). However, this conclusion may be dubious as the 
differences in the coat thickness of pellets with various sizes were not 
considered during comparison. Clearly, smaller pellets coated to the same coat 
weight gain as the bigger pellets had thinner film coats owing to their larger 
specific area. Hence, the greater extent of coat damage observed for smaller 
pellets could be related to the lower mechanical strength of their thinner coat 
formed. In order to achieve a fair comparison, coated pellets with different sizes 
but the same coat thickness were compared with regard to their ability to 
withstand compaction force. Small coated pellets were observed to have 
significantly greater strength and their drug release was less affected by 
compaction than the larger pellets (Haslam et al., 1998). This finding suggested 
that reducing the size of the coated pellets may be effective in mitigating pellet 
coat damage caused by compaction. Nevertheless, the coating of small particles 
has always been a challenge due to the propensity of small particles to 
agglomerate.   
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1.4.2.3 Cushioning agents 
Cushioning agents in the form of either powders or agglomerated particles can 
be added in the MUPS tablet formulation. Ideally, the cushioning agents should 
function as surrogates to absorb the energy of compaction and prevent the 
coated pellets from rupture and damage during compaction. Moreover, at a low 
compaction force, the cushioning agents should also act as filler and binder in 
order to form MUPS tablets with sufficient mechanical strength. 
 
In response to the rate and magnitude of the applied force, as well as duration 
of the locally induced stress, materials with different mechanical properties 
exhibit different types of deformation, namely elastic deformation, plastic 
deformation and/or fragmentation (Çelik and Driscoll, 1993). For brittle 
materials such as a piece of glass, it is highly likely to fragment and break into 
pieces when compressed. This fragmentation generates many smaller pieces 
with sharp edges and points which may pierce into the pellet coat and cause 
indentations. Clearly, fragmenting materials are not ideal cushioning agents. For 
the materials which are able to deform under compaction forces, such as rubber, 
they usually absorb the compaction energy by changing their shape. However, 
such deformation can be either temporary or permanent. In the case of elastic 
deformation, the material goes back to its original shape once the loaded force 
is removed, like a spring. This is undesirable for tablet formation as the bonds 
formed between particles would be disrupted by the elastic recovery. A 
plastically deforming material is able to maintain the deformation even after the 
force is removed. For this kind of material, the extent of interparticulate bond 
formation can be facilitated by increasing the duration of force application. Thus, 
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plastically deforming materials may be able to form stronger tablets without 
damaging the coated pellets. 
 
Cushioning materials with different plasticity were compacted with enteric 
coated theophylline granules. Subsequently, the ability of these materials to 
cushion the coated granules were correlated with their yield pressure, above 
which irreversible plastic deformation occurs (Torrado and Augsburger, 1994). 
It was found that polyethylene glycol (PEG) 3350 had lower yield pressure than 
the coated granules and deformed preferentially under compaction force. 
However, although PEG 3350 showed superior protective effect for the coated 
granules during compaction, it formed matrix tablets with prolonged 
disintegration time. Consequently, the drug release was slowed down and not 
controlled exclusively by the coating membrane. On the other hand, crushing 
and damage to the coated granules were observed for tablets made with MCC 
and crospovidone. After optimization, a cushioning formulation containing 50% 
MCC, 25% PEG 3350 and 25% crospovidone was proposed for forming tablets 
with fast disintegration and minimal damage to the coated granules.  
 
Although plastic deformation is necessary to form mechanically strong and 
stable tablets, the mechanical stress caused by deformation should not be 
transmitted to the coated pellets and cause damage. Therefore, a material that 
exhibit directly occurring elastic recovery after decompression was postulated 
to dissipate the mechanical stress on the coated pellets (Picker, 2004).  Highly 
elastically deforming polysaccharide polymers, including carrageenans, 
chitosans and alginates, have shown superior cushioning effect for compaction 
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of coated pellets (Schmid and Picker-Freyer, 2009). These findings appear to be 
contradictory to those of Torrado and Augsburger (1994). This discrepancy 
might be due to the inherent insensitivity of the Heckel plot, where both the 
elastic and plastic components were taken into consideration (Paronen, 1986). 
Therefore, yield pressure may not be the most suitable parameter to correlate 
the material compressibility with their ability to cushion the coated pellets 
(Sonnergaard, 1999).  
 
Apart from the compressibility of cushioning materials, their particle size was 
also demonstrated to affect the extent of coat damage. In the study by Yao et al. 
(1998), a variety of excipients with different particle sizes were prepared and 
compacted with EC coated microcapsules. Although these excipients had very 
different deformation behavior, a critical particle size of 20 µm was found for 
each type of excipients to display sufficient cushioning effect. Below this 
particle size, the coated microcapsules could be well protected by all the 
investigated excipients and showed similar dissolution profiles to those of 
uncompacted microcapsules. However, the mechanism of the better cushioning 
effect observed for smaller particles, regardless of their deformation behavior, 
has not been elucidated. This observation was further corroborated by another 
study which introduced micronized lactose (ML) with median particle size of 2 
µm, as a cushioning agent (Chin, 2011). Although coarse lactose was brittle and 
fragmented during compaction, ML did not fracture into sharp-edged fragments 
during compaction and formed an elastic powdery coat around the coated pellets 
instead. It was further postulated that ML conferred protective effect through 
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higher interparticulate friction and longer particle rearrangement phase (Fell and 
Newton, 1971). 
 
Despite their superior cushioning effect, micronized excipients are not ideal for 
routine rotary tablet production owing to their poor flowability and 
compressibility. Because of the weak bonding forces between micronized 
particles, the resultant MUPS tablets were friable and prone to capping. 
Moreover, segregation between the cushioning agents and coated pellets may 
occur due to differences in their particle size, shape and density, compromising 
tablet weight uniformity and drug content. Wagner et al. (1999) compared the 
effect of five different grades of MCC on the pellet distribution in tablets 
prepared by a high speed rotary tablet press. The tablets comprising Avicel PH 
101 (median particle size of 50 µm) had the most uniform pellet distribution, 
regardless of the machine speed. On the contrary, pellet-containing tablets 
prepared with coarse MCC granules which were approximately equal in size to 
the coated pellets showed the least homogeneous pellet distribution. This 
difference in pellet distribution might be explained by the larger surface area 
and fibrous surface texture of the small-size MCC, forming a percolating 
infinite cluster to stabilize the pellets at their location in the mixture.  
 
In some other studies, it was found that size enlargement of the cushioning 
agents to form placebo beads of similar size to the coated pellets might 
potentially mitigate the problem of segregation. For example, inert cushioning 
beads containing plastically deforming MCC were produced by wet granulation 
or extrusion-spheronization (Wagner et al., 1999). Although MCC is highly 
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deformable and able to form strong tablets, the prepared pellets using water as 
binding liquid were observed to be hard and not easily deformable. Interestingly, 
replacing water with ethanol as the binding liquid increased the compactability 
of MCC-based placebo beads to some extent. However, the improvement was 
not effective in preventing pellet coat damage during compaction. Soft and 
easily deformable placebo beads were able to deform preferentially and absorb 
compaction energy, thus more effective in preserving the pellet coat integrity 
under compaction (Vergote et al., 2002). For instance, the deformability of 
MCC-based pellets could be modified by incorporation of a soft material such 
as glyceryl behenate (Iloañusi and Schwartz, 1998), glyceryl palmitostearate 
(Mount and Schwartz, 1996), glyceryl monostearate (Lundqvist et al., 1998) and 
PEG (Nicklasson and Alderborn, 1999, 2001). As the presence of these soft 
materials facilitated interparticulate bond formation during compaction, the 
resultant MUPS tablets exhibited higher tensile strength and prolonged 
disintegration time. The poor tablet disintegrating properties, however, retarded 
drug release from the MUPS tablets and even caused the loss of their multiple 
unit nature due to matrix formation. For instance, non-disintegrating matrix 
tablets which remained intact after 8 h dissolution testing were formed using 
soft waxy beads as cushioning agents (Vergote et al., 2002). To circumvent non-
disintegrating problem, sufficient amount of disintegrants had to be added into 
the tablet formulation. The requirement of fast disintegration and yet enough 
protective effect for coated pellets has complicated the formulation 
development of cushioning agents. Alternatively, highly deformable MCC- 
based pellets with high porosity could also be produced by freeze drying (Habib 
et al., 2002). In their study, a greater amount of binding liquid was added due to 
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the presence of high levels of MCC and different types of superdisintegrants, 
especially croscarmellose sodium. As a result, the freeze dried beads exhibited 
higher porosities and compactibility.  
 
In the study by Lin et al. (2011), a potential cushioning agent for compaction of 
coated pellets was developed by spray drying ML with various types of 
polymers. The co-spray dried materials generally exhibited improved 
cushioning effect and physical properties. However, due to the binding effect of 
polymers, prolonged tablet disintegration was observed even with the addition 
of superdisintegrant in the MUPS tablet formulation and using a low 
compaction force to prepare the tablets. Moreover, the stability of amorphous 
lactose in the co-spray dried materials, and the subsequent effect on the 
cushioning properties of these materials, have not been fully understood.  
 
1.4.2.4 Overcoat and undercoat 
Besides size enlargement of the cushioning agents, layering the cushioning 
agents as overcoats or undercoats onto the coated pellets was also explored as 
an alternative to avoid the segregation problem. The overcoats and undercoats 
are layered over and underneath the functional pellet coat, respectively. In some 
cases, polymeric materials can be employed together with cushioning excipients. 
Hydroxypropyl methylcellulose (HPMC) was chosen for overcoating EC-
coated pellets due to its aqueous solubility and ability to form a soft and pliable 
film (Chambin et al., 2005). However, the thin layer of HPMC was found to 
reduce the tablet tensile strength and also interfered with the dissolution 
performance by forming channels for the dissolution medium to diffuse through. 
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In another approach, MCC and mannitol were applied as the outermost 
cushioning layer on top of the polymer-coated pellets (Altaf et al., 1998). 
Although these cushion-layered pellets exhibited excellent flow properties and 
facilitated tablet disintegration, loss of extended release properties upon 
compaction was still observed. In addition, as the larger particle size of the 
multi-layered pellets decreased their available surface area for bond formation 
under compaction, the resultant tablets were found to be mechanically weaker.  
 
An undercoat consisting of polyethylene oxide (PEO) and HPMC was layered 
onto the drug loaded pellets before the extended release coating (El-Gazayerly 
et al., 2004). The cushioning effect was possibly associated with the self-sealing 
property of the undercoat, as the gel-forming PEO-HPMC layer hydrated and 
swelled, providing sufficient viscosity to seal the cracks formed in the extended 
release coating. However, the functional polymer coat was still damaged during 
compaction. Interestingly, it was later found that the incorporation of 
magnesium stearate as a glidant in the cushioning layer or as an undercoat 
effectively reduced the extent of pellet coat damage (Hosseini et al., 2013).  This 
improvement in the cushioning effect was likely due to a more efficient 
dissipation of the mechanical stress during compaction.  
 
 Despite all the promising results of multiple-layered pellets, it is technically 
difficult and time consuming to conduct several rounds of coating to apply 
multiple layers of coating onto the same batch of pellets, especially when the 
cost-effectiveness of the manufacturing process is of concern. Moreover, pellet 
size is likely to increase tremendously after applying multiple layers, which in 
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turn compromises the dosage strength and mechanical strength of the MUPS 
tablets. 
 
1.4.2.5 Proportion of coated pellets  
Apart from the particle size of cushioning agents, the tendency of cushioning 
agents and the coated pellets to segregate was also dependent on the proportion 
of coated pellets in the mixture. For tablets comprising enteric coated pellets 
and waxy cushioning beads, it was observed that increasing the proportion of 
coated pellets led to higher friability and decreased mechanical strength and 
disintegration time (Debunne et al., 2004). The soft and deformable material 
was postulated to form a continuous matrix in which the coated pellets were 
embedded, whereas increase in the proportion of coated pellets may disrupt this 
matrix. Nonetheless, too much waxy cushioning beads in the tablet formulation 
might result in poor disintegration (Lundqvist et al., 1997). In another study, 
when MCC and enteric coated pellets were compacted using a high speed rotary 
tableting machine, 70% (w/w) pellets in the mixture was found to be the critical 
level exceeding which more pronounced damage to the coating would occur 
(Wagner et al., 2000b). Reducing the proportion of pellets to 60% (w/w) was 
effective in mitigating the pellet coat damage but the flow properties of the 
mixture was compromised due to the increased proportion of MCC. Thus, 
fumed silica has to be added as a glidant in order to achieve good tablet mass 
and content uniformity. The ratio in volume between the coated pellets and 
excipients was also found to be a critical factor determining the content 
uniformity of the resultant tablets (Beckert et al., 1996). This observation could 
probably be elucidated by the theory of percolation threshold, i.e., the volume 
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of coated pellets in the mixture should be sufficient to form an infinite 
stabilizing cluster, preventing segregation between coated pellets and excipients.  
 
1.4.3 Process related parameters on the extent of pellet coat damage 
Although the effects of different formulation properties on the extent of pellet 
coat damage during compaction have been extensively studied, the mechanism 
of the compaction process is still not well understood. MUPS tablet 
formulations often consist of binary or multiple components and each 
component with different deformation behavior and compressibility. In one 
study, MCC pellets were produced by extrusion-spheronization and 
investigated for their degree of deformation and densification during 
compaction (Johansson and Alderborn, 1996). It was observed that the MCC 
pellets underwent predominantly deformation with only minute occurrence of 
fragmentation. This could possibly be related to the plastically deforming 
behavior of primary MCC particles. Yet, pellet fragmentation during 
compaction was not found even with addition of 80% (w/w) hard and 
fragmenting material into the pellet formulation (Nicklasson et al., 1999).  
Based on this knowledge, a four-stage mechanistic model that describes the 
compaction process of uncoated pellets was proposed as follows: 1) volume 
reduction by pellet rearrangement; 2) volume reduction by pellet local surface 
deformation; 3) bulk structure deformation and densification; 4) cessation of 
volume reduction and interparticulate bond formation due to reduced compact 




Figure 5. Schematic diagram showing the four-stage mechanistic model that 
describes the compaction process of uncoated pellets.  
Stage 1:  
Volume reduction by pellet 
rearrangement to fill inter-
particle voids 
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surface deformation and 
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Stages 3 and 4: 
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At low compaction pressure level, volume reduction takes place due to pellet 
rearrangement to fill inter-particle voids. At this stage, the main cause of coat 
damage is due to direct contact between pellets and punch/die-wall surfaces as 
well as pellet-pellet contacts. These contacts may lead to build up of high 
stresses locally and cracking of the pellet coat. With increasing application of 
compaction pressure, the pellets will start to deform extensively, including 
surface deformation and bulk deformation. Consequently, the transmitted forces 
between pellets spread out over a larger area of contact. 
 
1.4.3.1 Compaction pressure 
Most of the studies that investigated the compaction process of coated pellet 
focused on the effect of compaction pressure on extent of coat damage. 
However, the results were found to be inconsistent and dependent on other 
factors. For instance, pellets coated with various types of polymeric coat were 
used for compaction (Dashevsky et al., 2004). It was observed that with a 
flexible coat, the change in drug release rate was minimal regardless of the 
magnitude of compaction pressure used. On the contrary, for pellets with a more 
brittle coat, drug release increased with increasing compaction pressure. In 
some other studies, it was also shown that increasing the compaction pressure 
could reduce the rate of drug release (Bansal et al., 1993; Torrado and 
Augsburger, 1994). The slowing down of drug release rate was due to higher 
compaction pressure which enabled greater densification and produced tablet 
matrices with poor disintegration. Thus, the slowdown in drug release was a 




Although the compaction pressure/force is the most straight-forward parameter 
to be determined in a compaction cycle, it is regarded as a reaction of material 
to the volume reduction enforced by the punches (Marshall, 1989). Hence, the 
degree of pellet densification by volume was proposed as an independent 
variable for a more accurate analysis of the compaction process (Kühl and 
Mielck, 2002). In their study, the applicability of different mathematical models 
for characterizing the densification of cushioning agents and coated pellets was 
evaluated, including the Kawakita equation, the Heckel function and a modified 
Weibull function. It was found that for sugar spheres, stronger mechanical 
interactions were initiated when the pellet volume ratio exceeded the value of 
0.42.  
 
1.4.3.2 Speed and time of compaction  
Single station eccentric tablet presses have been widely used for compaction of 
coated pellets to form MUPS tablets. During tablet formation in a single punch 
tablet press, only the upper punch penetrates the die to compress the material 
whereas the lower punch remains immovable (except for deflection). As there 
is one set of die and punches in operation, the single station tablet press is easily 
instrumented and useful in measuring the axial forces exerted by both punches 
and the distance travelled by the upper punch (Palmieri et al., 2005). However, 
the densification process in the single station tablet press is uniaxial and low in 
punch velocity and does not reproduce the same conditions as the high-speed 
rotary tableting machine used in industrial production. Studies on compacts 
containing coated pellets prepared by a rotary press are limited and the 
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mechanism by which the pellet coats are damaged by compaction remains 
unclear (Wagner et al., 1999, 2000). 
 
The rotary tablet press, operating with a number of die and punch sets, is 
commonly used to produce commercial tablets (Picker-Freyer, 2008). The dies 
are mounted on a circular turret and both the die turret and punches rotate 
together during tableting. In operation, both punches pass the compaction roll 
and apply compaction pressure to the upper and lower side of the powders in 
the die, and thus the densification process is biaxial. Dwell time is defined as 
the time interval during which higher than 90% of the peak force is maintained 
by the punches during a compaction cycle (Vezin et al., 1983). Schematic 
diagrams of the compression profiles for the single punch tablet press and rotary 
tablet press are shown in Figure 6 (A) and (B), respectively. As can be seen, 
dwell time for the single punch tablet press is determined by the length of time 
that the peak pressure was kept constant whereas dwell time in the rotary tablet 
press is a measure of the time when the punch head flat area is in contact with 
the compaction roll (Tye et al., 2005). Due to the differences in punch velocity 
and mode of force application, the dwell time in the rotary tablet press is much 
shorter than that in the single punch tablet press. Therefore, the compression 
behaviors of the same material exhibited in the two machines may differ to a 
great extent (Roberts and Rowe, 1985). For plastically deforming and 
viscoelastic materials such as MCC and corn starch, they undergo time 
dependent deformation. Increasing the dwell time has been shown to extend 
time for interparticulate bond formation and thus improves the tensile strength 
of compacts. On the other hand, for brittle materials that undergo predominantly 
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fragmentation under compaction, the tensile strength of the compacts is 




Figure 6. Representative illustrations of compression profiles of (A) single punch 





Compaction simulators were developed to mimic the densification process of a 
rotary tablet press and used to study the mechanical factors involved (Bateman 
et al., 1989). Similar to eccentric tableting machines, compaction simulators use 
one set of die and punches. Therefore, it has been extensively applied in the 
development stage of new products as only a small amount of material is needed. 
The latest development of compaction simulator employs the same compression 
wheels used in the rotary tablet press and the same geometries, thus being more 
accurate in mimicking both displacement profiles and load profiles during a 
rotary compaction process (Picker, 2000). Vergote et al. (2002) used a 
compaction simulator to investigate the effect of compression time and 
precompression force on the properties of tablet formulations which contained 
various ratios of cushioning beads. Although the extent of plastic deformation 
of a formulation containing 50% (w/w) cushioning beads was found to 
significantly decrease with a higher punch velocity, no change in the drug 
release rate was observed. In another study, the sensitivity of blends containing 
coated pellets and cushioning beads to various compaction speeds (strain rate 
sensitivity, SRS) was examined using a compaction simulator (Cantor et al., 
2009). The plastically deforming cushioning beads were found to exhibit a 
much higher SRS than the coated pellets or the blends at different ratios. The 
reason for this difference was because the compaction speeds employed were 
not spaced far enough to differentiate the change in SRS of various formulations. 
The application of compaction simulators in studying the compaction of coated 
pellets has not been well established as it is still a relatively new technology. 
Moreover, the results have not always been satisfactory with limited knowledge 
on the accuracy and reliability of the data obtained (Picker‐Freyer, 2008). 
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1.4.4 Assessment of coat intergity of compacted pellets  
As discussed in section 1.4.1, the functional film coating of the pellets may be 
ruptured or deformed during a tablet compaction event. As a consequence of 
these structual changes to the coating, the functionality of the coated pellet 
would be altered or even lost. Considering the small particle size of pellets and 
the microstructure of the film coating, microscopic techniques are the most 
direct method for visualizing the surface property and structure of coated pellet 
after compaction. For example, the SEM has been extensively applied to 
examine the surfaces and cross-sections of MUPS tablets (Debunne et al., 2004; 
Abbaspour et al., 2008; Bashaiwoldu et al., 2011) and compacted pellets (Bansal 
et al., 1993; Altaf et al., 1998; Hosseini et al., 2013). Pellet coat rupture could 
be easily observed in the SEM photomicrographs, however, the pellet 
deformation might be difficult to identify, especially when the pellets are 
embedded in the tablet matrix and surrounded by other excipients. In order to 
obtain a more comprehensive observation of the compacted pellets, the MUPS 
tablets were deaggregated to retrieve the coated pellets (Tunón et al., 2003a). 
These retrieved pellets were subsequently analyzed for the changes in their 
porosity, coat thickness, surface area, shape and drug release. Although the 
SEM analysis is a straight-forward technique for observing the morphological 
and dimensional properties of the coated pellet, the changes could not be 
quantified for statistical comparison.   
 
For MUPS tablets containing modified release pellets, it is of primary 
importance to ensure that the dissolution profile of the MUPS tablet remains 
unchanged and similar to that of the coated pellets before compaction. Therefore, 
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the dissolution profiles of the coated pellets before and after compaction are 
compared to assess the coat integrity. Any significant change in the drug release 
rate of the coated pellets after compaction should be considered as a change in 
the pellet coat integrity. As mentioned in section 1.3.4, the in vitro dissolution 
tests are often carried out using compendial dissolution apparatus to 
characterize the drug release properties of modified release dosage forms. The 
pellet coat damage should, ideally, be reflected in the change in the drug release 
rate or pattern. There are a few types of methods for comparing the dissolution 
profiles across different formulations and they have been extensively covered 
in a number of review articles (O'Hara et al., 1998; Costa and Lobo, 2001). 
These methods can be classified into three categories depending on whether 
mathematical model fitting or analysis of variance are involved in the data 
processing, as shown in Table 2.  
 
1.4.4.1 Model independent methods 
The model-independent methods include exploratory data analysis, 
mathematical comparison and statistical methods, and they are most commonly 
used in assessing the pellet coat damage caused by compaction. These methods 
do not require fitting the dissolution data into mathematical models and allow 
for comparing formulations with different drug release mechanisms. 
Exploratory data analysis is often employed as the first step to perform graphical 
and numerical analysis of the dissolution data, where the data points with error 
bars corresponding to their standard deviation are plotted in one graph for visual 
examination. Two dissolution profiles can be considered as significantly 
different if their error bars do not overlap with each other in the graph.
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f1: difference factor; f2: similarity factor; MDT: mean dissolution time; VDT: variance of the dissolution time; RD: relative dispersion; tx%: percent 






Although this method is simple for first-step analysis, it is not quantitative and 
may be difficult to interpret when comparing between a number of dissolution 
profiles with different shapes.  
 
The ratio tests are relations between parameters obtained from the dissolution 
profiles of the reference and test formulations at the same time. Very often, the 
time taken for a certain percentage of drug to be released (defined as Txmin) and 
the percent dissolved drug within a certain period of time (defined as tx%) can 
be determined from the dissolution profile and used to calculate the ratio. 
Although this approach is simple, the comparison only considers a single point 
in the dissolution profile and may not be representative of the entire dissolution 
data set. Alternatively, mean dissolution time (MDT), which is the arithmetic 
mean value of the entire dissolution data points, could be employed to 
characterize the whole dissolution profile more accurately (Podczeck, 1993). 
Other parameters, including the variance of the dissolution time (VDT) and the 
relative dispersion (RD) of the concentration-time profiles are also derived from 
the whole set of data from a dissolution profile. The MDT, VDT and RD values 
have been applied in the assessment of pellet coat damage by a number of 
studies (Chopra et al., 2002; Tunón et al., 2003a).  
  
The pair-wise comparison commonly makes use of the difference factor (f1) 
and similarity factor (f2). These two parameters are also recommended by 
regulatory bodies such as the United States Food and Drug Administration (US-
FDA) and EMA as simple model-independent approaches for dissolution 
profile comparison (US-FDA, 1997a, 1997b; EMA, 1999). f1 calculates the 
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percent (%) difference between the two curves at each time point and is a 
measurement of the relative error between the two curves. f2 is a logarithmic 
reciprocal square root transformation of the sum of squared error and is a 
measurement of the similarity in the percent (%) dissolution between the two 
curves. As these two parameters tend to overlook intra-batch variation of test 
and reference batches, US-FDA also recommends that in instances where within 
batch variation is more than 15% coefficient of variation, a multivariate model- 
independent procedure is more suitable for dissolution profile comparison. 
 
1.4.4.2 Model-dependent methods 
The model-dependent methods require curve fitting the dissolution data points 
to mathematical models before they can be used for comparing dissolution 
profiles. Some of the mathematical models can be deduced from a theoretical 
analysis of the dissolution process such as the zero-order model. However, more 
often than not, empirical models are derived to mathematically correlate the 
dissolution profiles with some parameters. These mathematical models and 
derived parameters provide some insights into the drug release mechanisms. 
Generally, reasonably good fit to the model is necessary for an accurate 
interpretation of the drug release mechanism. However, in some cases where 
multiple drug release mechanisms are involved, it may be difficult to find 
suitable models to precisely describe the dissolution profiles. Some of the 
commonly used mathematical models for modified drug release systems include 
the zero-order, first-order, Higuchi and Korsmeyer-Peppas models. Their 






Table 3. Commonly used mathematical models applied for describing the dissolution profiles of modified release dosage forms.  
 M0, Mt and M∞ correspond to the drug amounts at time zero, cumulative amount of drug released at a particular time t and at infinite time, 
respectively. K0, K1 , Kh  and Kp  refer to the release kinetic constants obtained from the linear curves of zero-order, first-order, Higuchi and 
Korsmeyer-Peppas models, respectively.  n is the release exponent indicating the mechanism of drug release.
Mathematical model Equation Examples of systems for model application 
zero-order 
 
osmosis driven systems; matrix tablet systems containing drugs with low solubility 
(Varelas et al., 1995); dosage forms surrounded by a release rate controlling 




systems containing water soluble drug in porous matrix (Mulye and Turco, 1995) 
Higuchi 
 





dosage form in which the release mechanism is unknown or when more than one type 
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Multiparticulate drug delivery systems have applications in personalized 
medicine, such as flexibility of dose adjustment during manufacture, potential 
for administering chemically-incompatible drugs and different drugs in one 
dosage form, and customization of the drug release profile. However, to date, 
the advantages of these systems are still not fully utilized to achieve more 
efficient therapies based on patients’ needs. Therefore, a more comprehensive 
understanding on multiparticulates is necessary for a wider application of 
multiparticulate systems in the pharmaceutical industry.  
 
Swirling airflow was found to be advantageous when incorporated in the FS 
processor, such as improving drying capacity and enhancing process robustness 
in coating substrates of various sizes and shapes. However, there is still a need 
to further explore potential advantages, limitations and new applications of the 
recently developed FS processor. In particular, the use of the FS processor for 
coating irregular-shaped particles with wide size distribution has not been 
investigated. 
 
The modified drug release properties of coated multiparticulates are primarily 
affected by their film coating thickness and integrity. Dissolution studies are 
commonly conducted using the USP dissolution apparatus 1 and 2 to assess the 
functionality of the coated multiparticulates, such as coated pellets, in a 
modified release dosage form. The resultant bulk dissolution profile examines 
drug release behavior of the whole dosage form but not that of an individual 
coated pellet. As such, the data has limited application to identify the coat 
quality of an individual pellet. In addition, there remains an unmet need to 
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characterize the underlying drug release mechanism of one individual coated 
pellet.   
 
Although the rotary tablet press is commonly used for commercial tablet 
production, studies on compacts containing coated pellets prepared by a rotary 
press are limited. To assess the extent of the coat damage sustained, the change 
in drug release rate of the coated pellets before and after compaction has been 
the most commonly used approach. However, the bulk dissolution properties of 
MUPS tablets are often influenced by the tablet disintegration time. Moreover, 
the change in the overall dissolution rate alone does not provide insights into 
the mechanism of pellet coat damage under compaction. Hence, it is necessary 
to investigate the mechanism of pellet coat damage caused by compaction at an 
individual pellet level in order to elucidate appropriate formulation and process 
strategies for mitigating pellet coat damage.  
 
Having identified these research gaps, this study is undertaken to prove the 
following hypotheses: 
1) FS processor is capable of coating multiparticulates with irregular shape and 
wide size distribution in a rapid and uniform manner (Study A). 
2) The individual dissolution technique using 400-DS dissolution apparatus 7 
is useful for differentiating the coat quality of individual extended release 
pellets (Study B). 
3) During the compression of coated pellets, coat damage could be minimized 
by the choice of appropriate tablet formulation and optimal tableting 
parameters (Study C).  
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4) For a MUPS tablet, the extent of pellet coat damage could be assessed and 
quantified at individual pellet level (Study C). 
 
To test the aforementioned hypothesis, investigations were carried out with the 
following objectives:  
1) To explore the potential of the FS processor for coating irregular-shaped 
particles with wide size distribution (Study A) 
2) To optimize the dissolution parameters in the 400-DS dissolution apparatus 
7 for individual dissolution of extended release pellets and to compare this 
methodology with the USP dissolution apparatus 1 and 2 (Study B) 
3) To develop cushioning agents with optimal stability and protective effect 
for compaction of coated pellets (Study C) 
4) To employ a mechanistic approach that examines coat damage at an 
individual pellet level for investigating formulation and process strategies 
to minimize pellet coat damage during compaction in a rotary tablet press 
(Study C) 
 
The proposed research for this study on multiparticulate drug delivery systems 
would:  
1) Broaden the existing knowledge on the FlexStreamTM fluidized bed 
technology for small particle coating. The application of FS processor for 
small particle coating would allow greater flexibility in the formulation of 
coated multiparticulate drug delivery systems. 
2) Enable dissolution testing of individual pellets to differentiate the coat 
quality of individual extended release pellets and to elaborate their drug 
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release mechanisms. The assessment of coat quality of individual 
multiparticulates is essential to achieve the desired properties in the final 
dosage forms.  
3) Contribute to more comprehensive knowledge on the properties of 
cushioning agents and mechanism of pellet coat damage caused by 
compaction. The evaluation of effects of formulation and process 
parameters on the extent of pellet coat damage during the rotary compaction 
process of coated pellets will provide deeper insights into the development 

























Chapter 3.  
Materials and Methods 
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3.1 Materials  
3.1.1 Materials for Study A 
Paracetamol crystals (Granules India, India) were used as the model particles 
for coating. Kollicoat® Smartseal 30D (BASF SE, Germany), an aqueous 
dispersion of a co-polymer comprising methyl methacrylate and 
diethylaminoethyl methacrylate with macrogol cetostearylether and sodium 
lauryl sulfate as stabilizers, was used for the taste masking coat. The coating 
formulation, composing of 20%, w/w Kollicoat® Smartseal 30D, was 
plasticized with 5%, w/w triethyl citrate (Merck, Germany) before use. 
Colloidal silica (Aerosil® 200, Evonik Degussa, Germany) was used as an anti-
tack agent. Phosphate buffer saline (pH 7.4) and hydrochloric acid (6 M) were 
used in the drug release study and hydrochloric acid (0.1 M, pH 1.2) in coat 
weight analysis and coat uniformity assessment. Unless otherwise mentioned, 
water used was pure water (Milli-Q, Millipore Corporation, USA). 
 
3.1.2 Materials for Study B  
Commercially available α-lactose monohydrate (Granulac 200, Meggle Pharma, 
Germany), microcrystalline cellulose (MCC, Avicel PH 101, FMC Biopolymer, 
Ireland) and model drug metformin hydrochloride (USP grade, Granules India, 
India) were used to prepare drug loaded pellets. The EC coating dispersion 
(Surelease, Colorcon, USA) was diluted with water from 25%, w/w solids to 
15%, w/w solids and stirred for approximately 30 min before use. Acetonitrile 
(HPLC grade, Tedia, USA), acetic acid (analytical grade, Merck, Germany) and 
ultrapure water (Milli-Q, Millipore Corporation, USA) were used for individual 
pellet dissolution and high performance liquid chromatography (HPLC) 
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analysis of drug content. Unless otherwise mentioned, water used was pure 
water (Milli-Q, Millipore Corporation, USA). 
 
3.1.3 Materials for Study C 
Sugar pellets (355-425 μm; Pharm-a-spheres, Hanns G. Werner, Germany), 
HPMC (VLV, Dow Chemical, USA), polyvinylpyrrolidone (Plasdone C-15, 
Ashland, USA) and filtered isopropyl alcohol (IPA, Aik Moh Paints and 
Chemicals Private Limited, Singapore) were used as supplied. Metformin 
hydrochloride (USP grade, Granules India, India) was the model drug. 
Commercially available α-lactose monohydrate (Granulac 200, Meggle Pharma, 
Germany), mannitol (Mannitol 35, Roquette, France) were used to prepare 
cushioning agents by spray drying. The coating materials and water used were 
the same as described in section 3.1.2. Cross-linked polyvinylpyrrolidone 
(Polyplasdone XL, Ashland, USA) and magnesium stearate (M125; Productos 
Metalest, Zaragoza, Spain) were used as disintegrant and lubricant in the tablet 
formulation, respectively. Unless otherwise mentioned, water used was pure 
water (Milli-Q, Millipore Corporation, USA). Silica gel, magnesium nitrate 
(Merck Chemicals, Germany) and sodium chloride (Merck Chemicals, 
Germany) were used to prepared the required RH conditions, which correspond 




3.2.1 Study A - Coating of irregular-shaped small multiparticulates using 
the FS processor  
 
3.2.1.1 Jet mill classification of primary drug particles 
The paracetamol particles were fractionated using an air-jet classifier (50 ATP, 
Hosokawa Alpine AG, Germany) with feeding screw rotating speed of 3 rpm 
and classifier wheel rotational speed of 3000 rpm to separate the less than 80 
µm size fraction from the coarser particles. 
 
3.2.1.2 FS coating of primary drug particles 
The coating process was conducted in a FS processor module mounted on an air 
handling system (MP-1 Multi-processor, GEA Aeromatic-Fielder, UK). A 2 kg 
load of 80 - 710 µm size fraction paracetamol particles was introduced into the 
FS processor and coated to 20%, w/w coat weight gain. Coat weight gain was 
expressed as the percentage ratio of dry weight of coat material deposited to the 
weight of the cores used. During coating, in-process samples at 5, 10 and 15%, 
w/w coat weight gains were taken. The operating conditions for FS coating of 
drug particles are shown in Table 4. After coating, the coated particles collected 
were blended with 0.2%, w/w colloidal silica for 10 min in a double-cone 
blender (AR 400E, Erweka, Germany) and then stored in a sealed plastic bag at 





Table 4. Operating conditions employed for the FS processor for coating of drug 




Drug particles Pellets 
Inlet airflow rate (m3/h) 60 140a and 160b 
Atomizing air pressure (bar) 2.5 2.5 
Inlet air temperature (°C) 45 65 
Nozzle tip diameter (mm) 0.5 0.5 
Nozzle tip protruded level (mm) 1.2 1.2 
Distance between spray nozzle and 
powder bed (mm) 
10 10 
Coating suspension spray rate 
(g/min) 
6 20a and 12b 
Drying time (min) 10 10 
a for drug layering process in Study C; b for the EC coating process in Study C 
 
3.2.1.3 Characterization of coated particles 
3.2.1.3.1 Size and size distribution 
An accurately weighed sample of coated particles (50 g) were sized using a nest 
of sieves (Endecotts, UK) with aperture sizes chosen in a √2 progression from 
710 µm to 90 μm on a sieve shaker (VS1000, Retsch, Germany) vibrated at 1 
mm amplitude for 10 min. The weights retained on each sieve and collection 
pan were determined and the cumulative percentage weight undersize graph 
plotted. Particle mass median diameter (D50) was determined from the 
percentage weight undersize plot. Span, calculated according to Eq. (1), reflects 
the degree of homogeneity in particle size distribution. A smaller span value 







                                               (1) 
where D10, D50, and D90 are the particle sizes at 10, 50, and 90 percentiles of 
the cumulative percentage weight undersize plot, respectively.  
 
In this study, the 90 - 710 µm size fraction was considered as the usable fraction 
while particles with size greater than 710 μm were considered as agglomerates. 
Usable yield and degree of agglomeration were calculated using the following 









×100%                                                            (3) 
where Wuf, Wagg and Wtotal are the weights of particles from the 90 - 710 µm 
size fraction, larger than 710 μm oversize fraction and the total amount sampled, 
respectively.  
 
3.2.1.3.2 Shape analysis 
Particles from the 90 - 710 μm size fraction were subjected to shape analysis 
using an optical microscope (BX 61, Olympus, Japan) connected to a video 
camera (DXC-390, Sony, Japan) and computer. Images collected were analyzed 
using image analysis software (Image Pro, Version 6.3, Media Cybernetics, 
USA). A total of 100 randomly taken particles was examined for each sample. 
Particle circular fit is measured by roundness and particle elongation is 
described by the aspect ratio. For both roundness and aspect ratio values, a 
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perfect circle has a value of unity. Roundness and aspect ratio were calculated 










                                                                                                     (5) 
where l is the straight line connecting the two most distant points of the two-
dimensional particle outline, and b is the perpendicular width against l. 
 
Photomicrographs of the coated particles were taken using SEM (JSM-6010LV, 
JEOL, Japan) for the qualitative analysis of surface morphology. Samples were 
examined using secondary electron image detector with an accelerating voltage 
of 1.5 kV and spot size of 30. 
 
3.2.1.3.3 Coat weight analysis and coat uniformity 
Coat weight of each of the 7 sieved size fractions (ranging from 500 - 710 µm 
size fraction to < 90 µm size fraction) within a sample of coated paracetamol 
particles was determined. The coat weight gain, Coat (%, w/w), was estimated 
by taking approximately 100 mg of randomly sampled coated particles, 
accurately weighed, dissolved in 100 mL hydrochloric acid solution (0.1 M, pH 
= 1.2) and with appropriate dilution, the amount of paracetamol present 
determined as above. The amount of coat deposited (Wcoat) was calculated by 
deducting the amount of paracetamol present (Wcore) from the weight of sample 
coated particles taken for analysis. Thus, the Coat (%, w/w) could be calculated 
according to Eq. (6). The relative standard deviation (RSD) of Coat (%) for 
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coated particles was calculated according to Eq. (7). A lower RSD value 
signified better uniformity. For each size fraction, triplicate coat weight gain 





×100                                                                                        (6) 
RSD of Coat (%) = Standard deviation of Coat (%)/ Mean of Coat (%)×100                                           
(7)          
 
The sieved fractions of coated particles were subsequently re-classified into 
three main fractions as small (< 125 µm), medium (125 - 355 µm) and large (> 
355 µm) according to their size. The proportion of these three fractions was 
determined from the percentage weight undersize plot in size analysis. The 
theoretical coat ratios of particles in the three fractions were calculated from 
their proportion and theoretical coat weight gain, namely 5, 10, 15 or 20%. The 
actual coat ratios of particles in the three fractions were calculated as shown in 
Eq. (8): 
 
Actual coat ratio =  ∑ (Px)(Coatx)
n
i=1                                                                        (8) 
where Px and Coatx are the proportion and coat weight gain of coated particles 
within a specific size fraction x in a weighed amount of sample respectively, 
calculated from triplicate batches.  
 
3.2.1.3.4 Drug release study 
Dissolution tests were conducted in a USP dissolution apparatus 1 (2100 C, 
Distek, USA) with 900 mL dissolution medium maintained at 37 ± 0.5 °C and 
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baskets rotated at 100 rpm. In the first 30 min, phosphate buffer saline at pH 7.4 
was used as the dissolution medium to mimic salivary pH. At 30 min, 8 mL of 
6 M hydrochloric acid was added into each vessel to achieve a pH of 1.2, 
mimicking gastric pH. Aliquots of 1 mL were withdrawn at pre-determined time 
intervals and filtered through a membrane filter (0.45 µm). The amount of 
paracetamol present was determined by UV spectroscopy (UV-3101 PC, 
Shimadzu, Japan) at a wavelength of 243 nm. Triplicate runs were conducted 
for each sample. 
 
3.2.2 Study B - Evaluation of the coat quality of extended release pellets 
by individual pellet dissolution methodology  
 
3.2.2.1 Rheological properties of powder blends 
To determine the amount of water required for pellet production, the rheological 
properties of powder blends comprising 25%, w/w MCC, 25%, w/w lactose and 
50%, w/w micronized metformin (D50 of 24 µm), amounting to a total of 24 g, 
were determined using a mixer torque rheometer (Caleva Process Solutions, 
England, UK). Prior to each measurement, the rheometer was operated with an 
empty bowl to obtain the baseline torque. Dry powder sample was then 
introduced into the mixer bowl and mixed for 30 s. Torque generated by the dry 
powder was recorded for another 20 s. Pure water was added in stepwise 
increments of 15%, v/w and continuously mixed with the powder for 30 s. After 
each mixing phase, the torque value was recorded for another 20 s prior to the 
next liquid addition. The mean torque is a measure of the mean resistance of the 
mass to mixing. For a total of 19 water additions, the mean torque values 
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generated were plotted against the amount of water added. From the plotted 
curve, the maximum mean torque value (Tmax) and the amount of water (WTmax) 
corresponding to Tmax were determined.  
 
3.2.2.2  Preparation of drug loaded pellets by extrusion-spheronization 
An appropriate amount of powder (25%, w/w MCC, 25%, w/w lactose and 50%, 
w/w micronized metformin) was first blended in a double-cone blender (AR 
400E, Erweka, Germany) at 10 rpm for 20 min. The blended mixture was then 
transferred to a planetary mixer (Kenwood Major, UK) and moistened for 5 min 
with 28.8%, v/w pure water amounting to 80% of the WTmax obtained from 
mixer torque rheometry studies on the equivalent powder blend. The resultant 
wet mass was extruded at a screw speed of 85 rpm through a radial screw 
extruder (E140, Niro, UK) fitted with a screen of aperture diameter and 
thickness of both 0.8 mm. Extrudates were spheronized (S320, Niro, UK) on a 
30 cm cross-hatched frictional base plate rotated at 500 rpm for 5 min. The 
resultant pellets were dried in a fluidized bed dryer (Strea-1, GEA-AF, UK) set 
with an inlet temperature of 80 °C. The drying process was stopped when the 
monitored product temperature reached 40 °C. The pellets were then subjected 
to further drying in an oven at 60 °C for 12 h. 
 
3.2.2.3 Preparation of extended release pellets by fluidized bed coating 
Drug loaded pellets (710 - 1000 μm) weighing 250 g were transferred into 
Wurster fluid bed coater (Strea-1, GEA-AF, UK) and coated with aqueous EC 
dispersion to produce extended release pellets with 8% and 10%, w/w coat 
weight gains (designated, 8% coat and 10% coat batches, respectively). The 
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process parameters used were as follows: inlet air volume, 80 m3/h; inlet 
temperature, 60 °C; product temperature, 38 °C; spray rate, 3-5 g/min; and 
atomization pressure, 1.2 bar. The coating dispersion was delivered by a two-
fluid spray nozzle with a nozzle tip of 1.2 mm and set to protrude at 1 mm from 
the flushed bottom position. After coating, the pellets were oven dried at 60 °C 
for 12 h. The fines and agglomerates were fractionated using sieves with 
aperture sizes of 710 µm and 1400 μm, respectively. 
 
3.2.2.4 Characterization of extended release pellets 
3.2.2.4.1 Size and size distribution 
Pellets were sieved through a nest of sieves with aperture sizes chosen in a √2 
progression from 1000 to 355 μm on a sieve shaker (VS 1000, Retsch, Germany) 
at 1 mm amplitude for 10 min. The determination of D50 and Span value of 
pellets followed the same procedure as that described in section 3.2.1.3.1.  
 
In addition, extended release pellets with 8% and 10% coats were passed 
through the 850 μm aperture size sieve and gently re-sieved using the same sieve. 
Pellets trapped in the sieve mesh were carefully extricated using a soft brush, 
for later use in the shape, coat thickness measurement, individual pellet weight, 
drug content analyses and individual pellet dissolution studies. 
 
3.2.2.4.2 Shape analysis  
The aspect ratio and roundness measurement for the 850 µm pellets was 




3.2.2.4.3 Pellet coat thickness measurement by SEM 
Extended release pellets with 8% and 10% coats were sliced equatorially using 
a razor blade. SEM was used to obtain photomicrographs of the pellet cross-
sections at 80 times magnification, as described in section 3.2.1.3.2. The pellet 
coat thickness measurements were made from the photomicrographs by using 
the imaging software (InTouchScope Software, JEOL, Japan). Ten random 
measurements were made for each pellet cross-section and ten pellets were 
sampled for each batch. 
 
3.2.2.4.4 Individual pellet weight  
A sample of 50 pellets was accurately weighed (AG 135, Mettler Toledo, USA) 
to calculate the averaged individual pellet weight (Ws). Triplicated 
measurements were conducted for extended release pellets with 8% and 10% 
coats and results averaged. 
 
3.2.2.4.5 Drug content 
One 850 µm size pellet was sampled randomly and ground with a mortar and 
pestle. The resultant powder was transferred into a 25 mL volumetric flask, 
water added and sonicated for 10 min to completely dissolve the drug. After 
making up to volume, the solution was filtered through a 0.45 μm membrane 
filter (Regenerated Cellulose, Sartorius Stedim Biotech, Germany) into vials. 
The vials were then assayed using reversed-phase HPLC (SIL-10AD VP, LC-
20AT VP, Shimadzu, Japan) with the octadecyl-silica C18 column (150 × 4.6 
mm, 5 μm; Hypersil, Thermo Scientific, USA) at 40 °C and a diode array 
detector (SPD - M10A VP, Shimadzu, Japan) set at a wavelength of 233 nm. 
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Mobile phase of acetonitrile, ultrapure water and acetic acid (55:47.75:0.25, 
v/v/v, respectively) was delivered at flow rate of 0.5 mL/min and an injection 
volume of 10 μL was applied. The drug content (%) was calculated by the 
percentage quotient of assayed amount of metformin and Ws. For the extended 
release pellets with 8% and 10% coats, 25 pellets from each batch were 
subjected to drug content measurement and results averaged. 
 
3.2.2.5 In vitro dissolution studies 
3.2.2.5.1 Drug release from ensembles of pellets 
Dissolution studies were conducted using USP dissolution apparatus 1 and 2 
(9ST, Caleva, UK) with 900 mL pure water maintained at 37 ± 0.5 °C and stirred 
at 100 rpm. At predetermined time intervals, samples of 5 mL were withdrawn 
and filtered (0.45 µm). The amount of metformin was determined 
spectrophotometrically (3101 PC, Shimadzu, Japan) at 233 nm. The final 
sample was withdrawn after rotating the baskets at 300 rpm for 30 min to ensure 
complete drug release. Runs were triplicated and results averaged. From the plot 
of cumulative drug release (%) against time, T10% and T50%, the times required 
for 10% and 50% drug release were determined. Model-independent 
comparison of dissolution profiles was carried out using the difference factor 
(f1) as calculated by Eq. (9). Two dissolution profiles are considered similar 
when the f1 value falls in the range of 0 to 15 (Moore et al., 1996). 
 
The in vitro drug release data were fitted to three release kinetics models which 
are commonly used for extended release dosage forms, namely zero-order, first-
order and Higuchi models, employing Eqs. (10), (11) and (12), respectively. 
 67 
 
The best-fit model was identified by evaluating the coefficient of determination 









 ×100                                                                                                                  (9) 




⁄ ) = K1t                                                                                                                         (11) 
Mt = Kh√t                                                                                                                                          (12) 
where n is the number of time intervals in which the samples were withdrawn, 
Ri and Ti are the mean percentage drug release for the reference and test sample 
at time interval i, respectively. M0 and Mt correspond to the drug amounts at 
time zero and dissolved at a particular time t, respectively. K0, K1 and Kh refer 
to the release kinetic constants obtained from the linear curves of zero-order, 
first-order and Higuchi models, respectively.  
 
3.2.2.5.2 Drug release from individual pellet 
Five coated pellets were randomly selected and subjected to drug release test 
using the dissolution apparatus 7 (400-DS, Agilent Technologies, USA) in 
ultrapure water as dissolution medium maintained at 37 ± 0.5 °C by heating 
jackets around the dissolution cells. The schematic diagram of a dissolution set 
in 400-DS dissolution apparatus 7 and the illustration of one dip cycle during 
the dissolution study is shown in Figure 7. At the end of each dip interval, 1.5 
mL of the medium was withdrawn through the auto-sampling port at the base 
of the dissolution cell into a HPLC vial on the sample collection tray. An 
equivalent volume of fresh medium was then introduced by a fluidic module. 
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The amount of drug released in each dip interval was assayed and percentage 
drug released for one pellet at all dip intervals during the dissolution run were 
averaged to obtain the percentage drug release in each dip interval for the pellet 
(Rx) and the standard deviation of percentage drug release (SDx) was also 
determined. For a total of five pellet samples in each run, the average percentage 
drug release in each dip interval (Ravg)  and the standard deviation of percentage 













i=1                                                                                                                  (14) 
 
Cumulative drug release profiles over a period of 240 min under optimized 
settings in 400-DS were also plotted for individual extended release pellets with 










3.2.2.6 Design of experiment 
A three-level, three-factorial Box-Behnken experimental design was used to 
evaluate the effects of the following design variables: A - dip speed (DPM); B 
- dip interval (min); C - volume of dissolution medium (mL), on the response 
variables. The objective of the design was to optimize the operating parameters 
used for conducting drug release test of individual pellet in the 400-DS 
dissolution apparatus 7 so that an appropriate amount of drug would be released 
within each dip interval and the variability would be minimal. The variability in 
drug release could be characterized by the standard deviation of inter-pellet 
percentage drug release rates. Hence, Ravg and Rstd were chosen as the response 
variables in the design. The design variables along with their low, medium and 
high levels which were decided based on the results of preliminary experiments 
and together with response variables selected, are shown in Table 5. Based on 
the settings selected, 17 experiments, including 5 center points, were generated. 
These center points could be used to check for non-linearity and reproducibility 
of the system. Hence, no further replication of the design was needed. The 
experiments were conducted in a randomized order to reduce the effects of any 
possible factors that were not included in the study, particularly effects that were 
time-dependent. The possible effects of the design variables on the response 
variables were examined by fitting the responses to a least-order polynomial 
model using response surface methodology (RSM). Process optimization was 
then carried out based on the following criteria: (a) Ravg should be within 10 -




Table 5. Design variables for individual dissolution study of extended release 
pellets in 400-DS dissolution apparatus 7. 
 
Order  Design variables 








1 1  10 20 9 
16 2d  20 40 9 
5 3  10 40 6 
6 4  30 40 6 
8 5  30 40 12 
10 6  20 60 6 
7 7  10 40 12 
11 8  20 20 12 
17 9d  20 40 9 
13 10d  20 40 9 
3 11  10 60 9 
12 12  20 60 12 
14 13d  20 40 9 
2 14  30 20 9 
9 15  20 20 6 
15 16d  20 40 9 
4 17  30 60 9 
c Std Order refers to the original order of the design while Run Order refers to 
the exact running order of the experiments after randomization 
d denotes center points of the Box-Behnken design 
 
3.2.2.7 Statistical analysis 
Statistical analysis and process optimization were carried out using Design-
Expert (Version 8.0.7.1, Stat-Ease Inc., USA). The response surface modelling 
was performed by a sequential procedure of collecting experimental data from 
each dissolution study, estimating polynomials and checking model adequacy. 
Regression analysis was conducted in coded units, where low level was coded 
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as −1 while high level was coded as 1. The level of significance was defined as 
p < 0.05. 
 
Process optimization was conducted by Response Optimization of Design-
Expert software. Once a significant model for a response variable was generated, 
it formed the design space for this response variable and its desired value range 
could be input to predict the contributing design variables. Triplicate 
confirmation runs with 5 pellets for each run were subsequently conducted using 
the optimized parameters to check the validity of the models generated by RSM. 
The responses were averaged and compared with 95% prediction interval of the 
predicted value. 
 
3.2.3 Study C. Part 1 - Development of cushioning agents with optimal 
stability and protective effect for compaction of coated pellets  
 
3.2.3.1 Preparation of ML 
Comminution of lactose particles was carried out using an air-jet mill (100 AFG, 
Hosokawa Alpine AG, Germany) with a classifier wheel rotational speed of 
18000 rpm. Prior to the milling process, lactose powders were sieved through 
500 µm aperture size sieve and dried in the hot air oven at 60 °C for at least 6 h 
and stored in a desiccator overnight.  
 
3.2.3.2 Preparation of spray dried ML-mannitol particles 
Briefly, three concentrations of mannitol, namely 1%, 2% and 4% w/w were 
dissolved in saturated lactose solution (20%, w/w). Correspondingly, the ratio 
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of dissolved lactose and mannitol in the resultant solution was 20:1, 10:1 and 
5:1 (w:w), respectively. ML was then uniformly dispersed in ice-cold saturated 
solution of lactose containing the different concentrations of dissolved mannitol 
to form the feed dispersions. The ratio of dispersed ML to dissolved lactose in 
the feed dispersion was fixed at 2:1 (w:w). The formulation codes for spray 
dried materials are summarized in Table 6. Each prepared feed dispersion was 
immediately spray dried using a pilot scale spray dryer (Mobile Minor, Niro, 
Denmark). The operating conditions in the spray dryer are summarized as 
follows: inlet temperature, 140 °C; outlet temperature, 80 °C; feed rate, 
approximately 30 mL/min. Unless otherwise mentioned, the mode of liquid 
spray employed was the two fluid spray nozzle with an atomizing air pressure 
of 1.5 bar. A rotary atomizer was used to prepare sML_Man2_L, with an 
atomizing wheel speed of 23000 rpm.  
 
Table 6. Summary of the formulation codes for the spray dried materials. 
 
Formulation code 




sLac 20 - - 
sMan - 20 - 
sML 20 - 40 
sML_Man1 20 1 40 
sML_Man2 20 2 40 
sML_Man4 20 4 40 





The spray dried products were collected and sealed in plastic bags after 
collection and stored in a desiccator at room temperature before further tests. 
Samples were also stored at desiccators containing silica gel (10.0% RH), and 
saturated salt solutions of magnesium nitrate (52.8% RH), and sodium chloride 
(75.3% RH) for 14 and 28 days. Subsequently, samples were characterized for 
their changes in the moisture content and percentage crystallinity, Cr (%), for 
analysis of their hygroscopic behavior and physical states of lactose in the 
samples, respectively.   
 
3.2.3.3 Characterization of spray dried ML-mannitol particles 
3.2.3.3.1 Size and size distribution 
Particle size was determined by the wet module of the laser diffraction particle 
sizer (LS 230, Coulter Corporation, USA). The materials were suspended in IPA 
and steadily delivered to achieve an obscuration of 8%. A total of three 
determinations were carried out for each material. The D50 and span values 
were determined from the cumulative percent undersize plot by volume, 
following the same procedure as that described in section 3.2.1.3.1. 
 
3.2.3.3.2 Compressibility 
A tap density tester (USP II, TD2, Sotax, USA) was used for compressibility 
investigations. The sample was pre-sieved through a 500 µm aperture size sieve 
into a measuring cylinder, cut exactly to 20 mL. Excess powder was scraped off 
carefully with a spatula and the weight of the filled powder was accurately 
weighed (LC22015, Sartorius, USA). Tapping was carried out until no further 
change in volume was observed. Powder bulk density and tapped density were 
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calculated as quotients of the weight of the filled powder to its volume before 
and after tapping, respectively. The Hausner ratio and the Carr’s index were 
calculated according to Eqs. (15) and (16) 
 
Hausner ratio = 
tapped density 
bulk density
                                                                         (15) 
Carr's index =
tapped density - bulk density
tapped density
 ×100%                                                                 (16) 
   
3.2.3.3.3 Moisture content 
An accurately weighed sample of 1 g was dried at 105 °C for 30 min using a 
moisture balance (EB-330 MOC, Shimadzu, Japan). The moisture content of 
the spray dried powders was determined by dividing the weight loss after drying 
by the original weight of the sample. Triplicated runs were conducted for each 
sample and results averaged.  
 
The hygroscopic behavior of the powders was investigated by storing the spray 
dried powders in different desiccators containing saturated salt solutions, each 
maintaining a specific RH level depending of the salt. The moisture uptake by 
the spray dried materials was evaluated via moisture content measurement, at 
Day 14 and Day 28.  
 
3.2.3.3.4 Physical states of lactose 
The physical states of lactose in the materials were determined by X-ray 
diffraction (XRD) and differential scanning calorimetry (DSC). X-ray 
diffractograms of the materials were obtained using an X-ray diffractometer 
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(XRD 6000, Shimadzu, Japan). A monochromatic Cu Kα radiation source was 
operated at 40 kV and 30 mA with a step size of 0.02° and a scan speed of 
2°/min over a range of 10-50° (2θ). The diffractometer was calibrated using a 
silicon standard. The Cr (%) was calculated using the integral method 
introduced by Wakelin et al. (Wakelin et al., 1959). The diffraction pattern of 
the lactose re-crystallized from an aqueous solution of lactose at 60 °C was used 
as the crystalline reference and the pattern of sLac was used as the amorphous 
reference.  
 
The thermal properties of samples were characterized by DSC (DSC-60, 
Shimadzu, Japan) in the temperature range of 30 - 250 °C with a scanning rate 
of 10 °C/min. An accurately weighed sample was spread as a mono-layer and 
sealed in an aluminum pan and measured under a nitrogen atmosphere. An 
empty sealed aluminum pan was used as reference and calibration was carried 
out using indium standards. 
 
3.2.3.4 Preparation of coated pellets 
The sugar cores were first coated with the drug layer followed by the release-
controlling membrane using the FS processor. For drug loading, 2 kg cores were 
coated using the operating conditions shown in Table 2. A 7331.4 g drug 
layering solution containing 6%, w/w HPMC, 1%, w/w polyvinylpyrrolidone 
and 20%, w/w metformin hydrochloride, was sprayed using a two fluid nozzle. 
The theoretical percent increase in dry weight of cores after drug layering was 
100%. The drug-layered pellets were hot air oven dried at 60 °C for about 12 h. 




Next, the drug-layered pellets were over-coated with EC using operating 
conditions shown in Table 2. The aqueous EC dispersion was diluted from 25%, 
w/w solids to 15%, w/w solids and stirred for about 30 min before use. The 
theoretical increase in dry weight after EC coating was 10%, w/w. After coating, 
the pellets were oven dried at 60 °C for 12 h and then fractionated, as described 
previously.  
 
3.2.3.5 Preparation of MUPS tablets containing EC-coated pellets and 
cushioning agents 
Each 750 mg tablet was prepared with 47.25%, w/w EC-coated pellets, 47.25%, 
w/w cushioning agents, 5%, w/w polyplasdone XL and 0.5%, w/w magnesium 
stearate. A rotary tablet press (R190 FT, GEA-Courtoy, Belgium) was used to 
prepare 14 mm diameter flat-faced bevel edge tablets, employing two 
compaction pressures of 43 and 60 MPa. The resultant MUPS tablets were 
coded by the cushioning agents used, namely, T_ML, T_sML, T_sML_Man1, 
T_sML_Man2 and T_sML_Man4. 
 
3.2.3.6 Evaluation of MUPS tablets 
3.2.3.6.1 Thickness and tensile strength 
After aging for 3 days, the thickness and breaking force of the tablets were 
determined using a digital micrometer (Mitutoyo, Japan) and a tensile strength 
tester (TBF 1000, Copley Scientific, UK). The effect of tablet thickness 





Tensile strength (N·mm-2)= 
2F
πDh
                                                                                 (17) 
where F, D and h are the measured breaking force, diameter and thickness of 
the tablet, respectively.  
 
3.2.3.6.2 Disintegration test 
The disintegration tests were conducted (Test A, Appendix XII A, BP 2016) 
using a disintegration tester (DT-2, Sotax, USA) in pure water maintained at 37 
± 1 °C. Six tablets of each formulation were used and results averaged. 
Disintegration time was used to indicate when a MUPS tablet starts to act as a 
true multiple-unit dosage form.  
  
3.2.3.6.3 Dissolution test 
The dissolution runs were conducted using USP dissolution apparatus 1, 
following the same procedure as that described in section 3.2.2.5.1. 
 
The similarity factor f2, which can be calculated by Eq. (18), was used to 
determine if any two dissolution profiles were similar or different. A f2 value 
between 50 and 100 indicates equivalence (Shah et al., 1998). According to the 
guideline from US-FDA, dissolution sampling time points below 85% drug 
release and only one point above 85% were used in the calculation of f2 (US-
FDA, 1997a).  
 
f2 = 50 × log {[1+( 
1
n




×100}                                              (18) 
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where n is the number of time intervals in which the samples were withdrawn, 
Ri and Ti are the mean percentage drug release for the reference and test sample 
at time interval i, respectively.  
 
The MDT value was calculated by Eq. (19) to represent the drug release rate. 
The 95% drug release, which was directly determined from each dissolution 
curve, was set as the ending point of calculation.  
 
MDT (min) = 
∑ ti̅×∆Mi 
∑ ∆Mi
                         (19) 
where ti̅ is the midpoint of the time period during which the fraction ∆Mi  of the 
drug has been released from the dosage form, i.e., ti̅= 
ti+ti+1
2⁄  and 
∆Mi = (Mi+1- Mi).  
 
3.2.4 Study C. Part 2 - A mechanistic approach for analyzing the pellet 
coat damage caused by compaction in a rotary tablet press 
Preparation of sML_Man2_L and coated pellets followed the procedures as 
described in section 3.2.3.2 and 3.2.3.4., respectively.  
 
3.2.4.1 Characterization of coated pellets 
Both the drug-layered and EC-coated pellets were characterized for their size 
and shape, crushing strength and coat thickness.  
 
3.2.4.1.1 Size and shape analysis by optical microscopy 
Particle size and shape analysis of the coated pellets were conducted using an 
imaging system connected to a stereomicroscope (SZ 61, Olympus, Japan). The 
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images of at least 500 randomly selected pellets were captured with a digital 
camera (DP 71, Olympus, Japan) and analyzed using an image analysis software 
(Image-Pro, Version 6.3, Media Cybernetics, USA). The size of coated pellets 
was measured by mean Feret’s diameter, defined as the average caliper length 
along a specified direction. The shape of the coated pellets was determined 
using aspect ratio and roundness, as described in section 3.2.1.3.2.  
 
3.2.4.1.2 Mechanical testing of coated pellets 
The crushing strength of the coated pellets was determined using a tensile tester 
(EZ test-100N, Shimadzu, Japan). Before analysis, the coated pellets were 
sieved through sieve with aperture size of 500 µm. Pellets lodged within the 
sieve apertures were gently brushed off and mounted between two platens and 
crushed at a rate of 0.5 mm/min. The load stress at break of the pellet was 
calculated from the first peak observed on the force-displacement plot.  A total 
of 30 pellets were crushed for each sample and the crushing strength was 
calculated using Eq. (20): 
 
Crushing strength (MPa) = 
load stress at break
π (Feret’s diameter )2
 × 4                                      (20) 
 
3.2.4.1.3 Coat thickness measurement by SEM 
 Samples were fixed using carbon paste on studs before being gold sputter-
coated (MSP-2S, IXRF Systems, USA). The coat thickness measurement was 
conducted according to section 3.2.2.4.3. Four random measurements were 




3.2.4.2 Determination of material true density 
The true volume of the EC-coated pellets and sML_Man2_L were determined 
by helium displacement pycnometery (Penta-Pycnometer, Quantachrome 
Instruments, USA) and true density was calculated by dividing the weight of 
sample by its true volume. Measurements were triplicated, and results averaged. 
 
3.2.4.3 Evaluation of material compression behaviors 
Compacts of the EC-coated pellets and sML_Man2_L, each weighing 1 g, were 
formed using a universal testing machine (Autograph, AG-100kNE, Shimadzu, 
Japan) fitted with 15 mm flat face punches and die set. Compacts were prepared 
with pressures ranging from 3.6 to 85.1 MPa. The die wall and punch faces were 
pre-lubricated with magnesium stearate suspended in IPA and dried before each 
compression cycle. The compression behaviors of materials were studied using 





) = kP + A                                            (21) 
where RD is the relative density of the compact at pressure P and it is obtained 
by dividing the apparent density of the compact by the true density of the 
material. k (slope; Heckel coefficient) and A (y-intercept) are the regression 
coefficients of the linear portion of the curve. Yield pressure, determined as the 






3.2.4.4 Preparation of MUPS tablets containing EC-coated pellets and 
sML_Man2_L 
Each 750 mg tablet was prepared with EC-coated pellets, sML-Man2_L, 5%, 
w/w polyplasdone XL and 0.5%, w/w magnesium stearate. The ratios between 
EC-coated pellets and sML-Man2_L were: 1:1, 3:2, 7:3 and 4:1 (w:w). A rotary 
tablet press (R190 FT, GEA-Courtoy, Belgium) was used to prepare 14 mm 
diameter flat-faced bevel edge tablets using a single compression roll attached 
to an air compensator. At the same turret speed and preset limiting force, the 
extension of dwell time could be achieved by adjusting the position of the 
compression roll. A more detailed description of the working principle for this 
rotary tableting press could be found in the study by Sarkar et al. (2013). A two 
factor three level full factorial design, including the dwell times (10, 25 and 40 
ms) and compaction pressures (20, 30 and 40 MPa), was employed to 
investigate the compaction process. The pellet volume fraction was calculated 
according to Eq. (22): 
 
Pellet volume fraction = 
Vp
Vapp
                                         (22) 
where Vp and Vapp are the true volume of the pellets and the apparent volume 
of the tablet, respectively. Vp is obtained by dividing the pellet weight by its 
true density and Vapp is calculated from the dimensions of the tablet. 
 
3.2.4.5 Evaluation of MUPS tablets 
Thickness and tensile strength, disintegration time and dissolution test were 
carried out to evaluate the MUPS tablets, following the methods as described in 
section 3.2.3.6.  
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3.2.4.6  Evaluation of EC-coated pellets in the MUPS tablet 
3.2.4.6.1 Excavation of individual pellets in the MUPS tablets 
As shown in Figure 8, twenty coated pellets from various sites located at the 
vicinity of the axial and radial peripheral surfaces and core of a MUPS tablet 
were carefully excavated by gently brushing the axial and radial peripheral 
surfaces and broken cross-section of the tablet, respectively, using a small soft 
brush. Excipient particles adhering on the surface of the pellets were then 













(A) (B) (C) 
Figure 8. Schematic diagram showing the coated pellets (●) located at the 
MUPS tablet (A) axial peripheral surface (tablet top view); (B) core (tablet 
cross-section) and (C) radial peripheral surface (tablet side view), respectively. 
 84 
 
3.2.4.6.2 Analysis of coat damage of excavated pellets 
Images of the excavated pellets obtained using SEM were examined for coat 
damage. A pellet coat damage index was proposed as the indicator of the extent 
of coat damage in terms of drug release from excavated pellets versus non-
compacted pellets. The drug release profiles of individual excavated pellets 
were obtained by subjecting one pellet to sonication (Sonorex, Germany) for 2 
min in 10 mL pure water. The amount of metformin released from one 
excavated pellet, Wm, was measured spectrophotometrically at 233 nm.  
 
Individual pellets were ground, dissolved in 10 mL pure water with sonication 
for 10 min and the amount of metformin determined spectrophotometrically at 
233 nm. The mean drug content of a pellet, Wt, was obtained using a bulk 
analysis with 100 pellets and result averaged. The pellet coat damage index was 
determined by calculating the ratio of Wm and Wt. Ratios close to one, between 













Chapter 4.  
Results and Discussion 
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4.1 Study A - Coating of irregular-shaped small particles using the FS 
processor 
The preferred size range of particles to be formulated into orally disintegrating 
MUPS tablet is less than 500 µm to avoid a gritty feeling in the mouth. Fluidized 
bed coating of small particles with size less than 500 µm is challenging due to 
their increased risks of overwetting and agglomeration. Hence, a modified 
fluidized bed processor with high drying efficiency is desirable to overcome 
these challenges. To date, studies on the FS processor are limited and its 
feasibility for coating irregular-shaped small particles has not been established. 
In this study, paracetamol drug particles with irregular shape and wide size 
distribution were directly coated in the FS processor to prepare taste masked 
particles. In-process samples with 5, 10, 15%, w/w coat weight gains and the 
resultant coated particles with 20%, w/w coat weight gain were collected to 
monitor the changes in their physicochemical attributes. The particle size, size 
distribution, shape, surface morphology, coat uniformity and drug release 
profiles of these coated particles were evaluated. 
 
4.1.1 Physical characterization of coated particles  
The coating process was reproducible in coating the paracetamol particles with 
a mean usable yield of 81 ± 3% and there was only minimal amount of 
agglomeration (< 5%). The physical properties of uncoated and coated particles 
with 5, 10, 15, and 20%, w/w coats were characterized to monitor their changes 
during the coating process (Table 7). There was a slight reduction in the D50 and 
increase in the span values of the in-process samples with 5% and 10% coats 
when compared with the uncoated particles. With more polymer coat deposited 
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on the particles, the D50 of the coated particles with 15% and 20% coats 
increased and span values decreased. The roundness and aspect ratio values 
decreased for the coated particles, up to 15% and 20% coats. The shape 
characteristics of coated particles with 15% and 20% coats were found to be 
more or less identical. SEM photomicrographs depicting the appearances of 
uncoated particles and coated particles with increasing coat deposition are given 
in Figure 9. As can be seen, the surfaces of uncoated particles demonstrated 
typical crystalline structure and were generally smooth. With the application of 
the taste masking polymer coat, the particle surfaces appeared rougher and their 
film coats became more complete and homogeneous with increasing coat 
weight gain, from 5% to 20%. 
 
Table 7. D50, span, shape factors of uncoated and coated particles with 5%, 10%, 
15%, and 20%, w/w coats. 
  
 
4.1.2 Effect of swirling airflow on the coating efficiency of the FS 
processor 
The high coating efficiency and low agglomeration tendency of the FS 
processor in coating the irregular-shaped particles could be attributed to the 
accelerated drying rate of the swirling airflow and presence of mild shear force 
during the fluidization (Wong et al., 2012).
Formulation code D50 (μm) Span Aspect ratio Roundness 
uncoated particles 230 1.39 2.04 ± 0.65 1.53 ± 0.40 
5% coat 182 1.88 2.22 ± 0.99 1.58 ± 0.46 
10% coat 222 1.56 1.99 ± 0.72 1.41 ± 0.28 
15% coat 243 1.42 1.62 ± 0.42 1.24 ± 0.12 







(B) (C) (D) (A) (E) 
Figure 9. SEM photomicrographs depicting the uncoated and coated particles (x 300 magnification) and their surface morphology (x 1000 
magnification); (A) uncoated particles, (B) 5% coat, (C) 10% coat, (D) 15% coat, (E) 20% coat. 
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In the spray coating process, the coating formulation was atomized into very 
fine droplets which subsequently impinged onto the surfaces of the core 
particles (Tang et al., 2008). Small particles with irregular shape have a high 
risk of excessive wetting during the coating process due to their large surface 
area to volume ratio. Their wetted surfaces, coupled with small sizes, may result 
in juvenile agglomerates composed of weakly held conjoined particles. In the 
FS processor, the bottom swirling airflow and tangential enveloping air 
provided a cross-current attritive shear force which helped to break up these 
agglomerates. Hence, the chances for small coated particles to permanently 
adhere due to their wetted surfaces were effectively reduced.  
 
The slight reduction in the particle size of the in-process samples with 5% and 
10% coats as compared with the uncoated particles could be due to some 
aerodynamic modification of the particle shape and surface morphology. At the 
start of the coating process, the primary particles were fluidized in the product 
chamber and exposed to the swirling airflow. These core particles would collide 
randomly and due to their irregular shapes, sometimes with protruding edges, 
they may be prone to abrasion under the initial attritive conditions. As such, the 
coated particles with 5% and 10% coats had slightly smaller D50 and larger span 
values when compared with the uncoated particles. The increase in D50 and 
decrease in span values for coated particles with 15% and 20% coats could be 
attributed to thicker coats formed on the particles with further coating as well 
as some minor agglomerative growth by particle layering as some fines may 
deposit on the larger counterparts despite being sheared by the swirling airflow 
in the FS processor. Similarities in the shape characteristics of the coated 
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particles with 15% and 20% coats implied that an optimal condition for coat 
formation had occurred and numerically constant particles were presented in the 
FS processor for the polymer coat dispersion to be deposited as the coating run 
progressed.  
 
Given the wide size distribution and irregular shape of the primary core particles, 
changes in particle size and shape during coating were considered to be only 
marginal with minimal agglomeration and slight attrition of the core particles 
initially, suggesting no significant particle breakage had occurred during the FS 
coating operation. This was because the shear force exerted by the swirling 
airflow in the FS processor was much milder due to its aerodynamic origin when 
compared with the centrifugal force generated by the rotating horizontal 
cylinder in the rotating fluidized bed, a popular processor for coating fine 
particles (Jono et al., 2000; Watano et al., 2004). The stronger centrifugal force 
in the rotating fluidized bed increased the risk of weak core particle breakage 
during the coating process and even rupture of the coat after formation. 
 
4.1.3 Effect of particle size on coat uniformity 
Pellet coat quality can be characterized by the mass coating variation or 
uniformity which refers to the variation in the amount of coating material 
deposited per unit weight of coated particles from a batch (Turton, 2008). The 
Coat (%) of coated particles in the various sieved size fractions were calculated 
by taking a weighed sample and deducting the assayed drug present for the coat 
weight gain of each sieved fraction. The RSD of Coat (%) of coated particles 
with 5 - 20% coat from the 7 sieved size fractions are plotted in Figure 10. As 
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can be seen, the particles with 5% coat presented the least uniform coat 
formation for all the 7 sieved size fractions and those with sizes smaller than 90 
µm and in the 500 - 710 μm size fraction exhibited much higher RSD of Coat 
(%) compared to those with size between 90 and 500 μm. This indicated that 
particles with 5% coat were not very uniformly coated, especially for the finer 
and coarser particles. For coated particles with 10%, 15% and 20% coats, the 
RSD of Coat (%) was observed to reduce significantly with increasing coat 
deposition and the differences between various size fractions were almost 
negligible. Such decreasing trend revealed that the amount of coat deposited per 
unit weight of core particles became more homogeneous with more polymer 











































Figure 10. RSD of measured coat weight gain of coated particles with 5% (♦), 
10% (■), 15% (▲), and 20% (●) coats from 7 sieved size fractions. 
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Classification of the coated particles according to their relative size, as small, 
medium and large, may provide further insights into the coat uniformity of 
particles with wide size distribution in the coated sample (Er et al., 2009). The 
proportions of coated particles in these three fractions are shown in Figure 11 
(A). For coated particles with increasing coat weight gain from 5% to 20%, the 
proportion of the small size fraction decreased from 30.19% to 3.15% whereas 
the proportion of the large size fraction increased from 13.29% to 21.97%. The 
proportion of the medium size fraction was also observed to increase from 56.52% 
to 74.32%. The theoretical and actual coat ratios of coated particles in the three 
fractions are given in Figure 11 (B). For coated particles with increasing coat 
weight gain from 5% to 20%, the actual and theoretical coat ratios of the small 
and medium size fractions were generally close to each other whereas their 
differences were observed to be much bigger for the large size fraction.  This 
suggested that coated particles in the small (< 125 µm) and medium (125 - 355 
µm) size fractions were more efficiently coated as their actual coat ratios were 
close to the theoretical coat ratios. The much lower actual coat ratio of particles 
in the large size fraction compared to the theoretical ratio indicated that particles 
larger than 355 µm had been under coated during the FS coating operation.  
 
Upon exposure to the swirling airflow in the FS processor, the smaller and 
lighter particles tended to be fluidized to higher regions in the product chamber, 
and project larger trajectories when being circulated. Thus, the relative 
circulation rate and the number of passes through the coating zone could be 
considerably reduced. This could be a possible reason for the higher RSD of 
































































Figure 11. (A) Proportion by weight of coated particles with 5%, 10%, 15%, and 
20% coats from the small (< 125 μm, ░), medium (125 - 355 μm, ≡) and large 
(> 355 μm, ∥∥) fractions; (B) Theoretical (open symbols) and actual (closed 
symbols) coat ratios of the coated particles with 5%, 10%, 15%, and 20% coats 
from the small (○, ●), medium (□, ■) and large (Δ, ▲) fractions, respectively. 
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On the other hand, the lower actual coat ratio for coated particles larger than 
355 µm may be due to weight related segregation and their tendency to remain 
around the lower sector of the fluidized powder bed during the coating process.  
 
In order to maintain a well fluidized powder bed during the coating operation, 
a rather low fluidization airflow was employed to avoid over-fluidization. As a 
result, larger and heavier particles failed to be projected higher in the fluidized 
powder bed because of the low upward fluidization airflow employed. Thus, the 
coarser particles showed lower levels of coat deposition. This finding suggested 
the need for tighter size distribution of core particles to be used for FS coating 
if coat uniformity is to be improved further.  
 
4.1.4 Drug release properties and taste masking efficiency 
Figure 12 depicts the drug release profiles of uncoated particles and coated 
particles with 5 - 20% coats in pH 7.4 medium for 30 min followed by a change 
to pH 1.2 medium, and dissolution run continued to 120 min. As can be seen, 
the uncoated paracetamol almost completely dissolved within 10 min (97.7%) 
upon exposure to pH 7.4 medium. The application of a taste masking polymer 
coat significantly reduced the drug release rate of the particles. Moreover, 
dissolution rates further decreased with an increase in the amount of applied 































































Figure 12. Drug release profiles of uncoated particles (○) and coated particles with 5% (♦), 10% (■), 15% (▲), and 20% (●) 




The drug concentration in the dissolution vessel after 4 min dissolution testing 
at salivary pH (pH 7.4) for the uncoated particles and particles with 5, 10, 15 
and 20% coats were 58.0 ± 0.9, 31.9 ± 1.5, 10.5 ± 0.8, 5.5 ± 0.5 and 2.9 ± 0.6 
µg/mL, respectively. A drastic increase in the dissolution rate could be observed 
immediately after acidification of the dissolution medium from pH 7.4 to 1.2. 
When the pH of the dissolution medium was changed to gastric condition (pH 
1.2), complete drug release was achieved within 15 min for particles with 5%, 
10%, and 15% coats whereas a longer period of 60 min was needed for complete 
drug release from the particles with 20% coat. 
 
4.1.5 Effect of coat weight gain on taste masking efficiency 
Increase in coat thickness corresponded to a decrease in drug release rate due 
primarily to the thicker diffusion barrier presented (Cuppok et al., 2011). This 
relationship, however, may not be linear and varies significantly with the 
properties of both the active ingredient and the polymer coat formed. In the case 
of particle coating for taste masking, an optimum coat thickness is desirable to 
allow for fast dissolution in the soluble pH range of the polymer coat while 
maintaining sufficient sealant properties in the polymer insoluble pH range. 
Paracetamol has been widely used as a model drug for the development of taste 
masking formulations and the in vitro dissolution profile of the developed 
dosage forms has been commonly used to evaluate their taste masking 
efficiency (Suzuki et al., 2003; Albertini et al., 2004; Shiino et al., 2010; 
Maniruzzaman et al., 2012). The percentage drug release within an early time 
point (e.g. ≤  5 min) has been recommended by FIP/AAPS (Federation 




Scientists) guidelines as an approximation of the bitter taste for ODTs (Siewert 
et al., 2003; Anand et al., 2007). The study by Shiino et al. found the human 
threshold for identifying the bitterness of paracetamol to be 35 μg/mL when the 
dissolution tests were carried out using the paddle method listed in the Japanese 
Pharmacopoeia with a dissolution medium volume of 900 mL (Shiino et al., 
2010). Therefore, taste masking efficiency could be evaluated by whether the 
drug substance is released or the released amount is below the human threshold 
for identifying its bitter taste within an early time point in the dissolution profile.  
 
Paracetamol is known to exhibit three polymorphs, namely two crystalline 
polymorphs, monoclinic [form I] and orthorhombic [form II], and an unstable 
amorphous phase [form III] (Al-Zoubi et al., 2002). The USP grade paracetamol 
employed as the model drug in the present study comprises monoclinic crystals. 
As the conversion between different paracetamol polymorphs is unlikely to 
occur under the process conditions during FS coating, the influence of 
paracetamol polymorphism on the drug release of coated particles should be 
minimal (Perlovich et al., 2007). For coated particles with 15% coat, the 
paracetamol concentration after 4 min dissolution in salivary pH was 5.5 ± 0.5 
µg/mL, which was 6 times lower than the human threshold for bitterness. Hence, 
despite the observed differences in the coat uniformity of the various particle 
size fractions, the overall drug release profile of coated particles with 15% coat 
demonstrated that a 15% coat weight gain was adequate as a sealant to taste 
mask the drug by sustaining drug release from the coated particles in salivary 





4.1.6 Application of taste masked drug particles with small size for ODT 
platforms 
Owing to the swirling airflow and the low pressure airflow extracted from the 
inlet plenum, the FS processor exhibited high drying efficiency and the 
capability to prevent particles from depositing around the spray nozzle, thereby 
preventing localized over-wetting by material deposition.  Although the coarser 
particles in the large size fraction were under coated, the FS processor with 
swirling airflow was shown to be able to coat irregular-shaped drug particles of 
wide size distribution with minimal agglomeration. The drug particles coated to 
15% coat weight gain were sufficiently taste masked and close to the size range 





4.2 Study B - Evaluation of the coat quality of extended release pellets 
by individual pellet dissolution methodology  
In pellet coating, data on drug release properties of individual pellets could help 
in process optimization, especially in identifying the uniformity of the spray 
application process. Therefore, a dissolution technique that allows profiling of 
single pellet drug release would be desirable for the examination of individual 
dissolution characteristics. The 400-DS dissolution apparatus 7 uses a 
reciprocating motion to dip a dosage form in the dissolution medium for a 
predetermined period of time, defined as dip interval. In a diffusion controlled 
dissolution process, the drug release rate from the dosage form is a combinative 
effect of the intrinsic drug diffusion rate and the operating parameters of the 
dissolution apparatus, namely the dip speed, dip interval and volume of 
dissolution medium. In this study, extended release pellets with two levels of 
coat thickness were prepared and their drug release profiles were characterized 
using the USP dissolution apparatus 1, 2 and 7. The operating parameters in the 
400-DS dissolution apparatus 7 for individual dissolution of extended release 
pellets were optimized by a three-level, three factorial Box-Behnken design. 
Using the optimal dissolution condition, the individual pellet dissolution profile 
obtained using dissolution apparatus 7 was compared with the bulk/ensemble 
dissolution profile using USP dissolution apparatus 1 and 2, for their capability 





4.2.1 Physicochemical characteristics of extended release pellets 
The physicochemical characteristics of extended release pellets with 8% and 10% 
coats are summarized in Table 8. The theoretical drug loading of 50%, w/w was 
found to be very close to the assayed content values of 48.7 ± 4.0% and 49.5 ± 
3.5% for the pellets with 8% and 10% coats, respectively. The two types of 
pellets were similar in their median pellet size, span, shape and individual 
weight. The D50 values were found to be between 800 - 900 µm and the span 
values were around 0.4, indicating narrow size distributions of the pellets. The 
roundness and aspect ratio values were close to 1 and average individual pellet 
weights of the two types of pellets were approximately 500 µg. The measured 
coat thickness of pellets with 8% and 10% coats were 13.9 µm and 15.7 μm, 
respectively. The examples of cut pellets with 8% and 10% coat are shown in 
Figure 13. The coat thickness of these two batches of extended release pellets 
differed by less than expected. However, the RSD of pellets with 10% coat was 
found to be much lower (5.9%) than that of pellets with 8% coat (15.7%), 
indicating more uniform coat formation of pellets with 10% coat.  
 
4.2.2 Drug release behavior of ensemble pellets in dissolution apparatus 
1 and 2 
It has been established that the underlying mechanism of drug release from 
pellets coated with EC was primarily by drug diffusion through the water 
insoluble polymeric semi-permeable membrane, irrespective of the type of 
pellet core and release medium, and the pellet diameter remained relatively 








         Table 8. Physicochemical properties of extended release pellets with 8% and 10% coats. 













8 813 ± 24 0.35 ± 0.01 1.11 ± 0.05 1.13 ± 0.01 516 ± 10 48.7 ± 4.0 13.9 ± 2.2 [15.7%*] 
10 849 ± 56 0.40 ± 0.03 1.10 ± 0.05 1.12 ± 0.01 513 ± 8 49.4 ± 3.5 15.7 ± 0.9 [5.9%*] 
(B) (A) 
Figure 13. SEM photomicrographs showing the cross-section of extended release pellets with (A) 8% and (B) 10% coat. 
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Therefore, in Study B, any change in pellet diameter during dissolution was 
assumed to be minimal. The following mass transport sequence was proposed 
for such system upon oral administration: water penetration into the system, 
partial dissolution of the drug and diffusion of dissolved drug out through the 
film coat into the surrounding bulk fluid. The drug diffusion process is the rate-
limiting step during the dissolution run. In this study, the pellet core produced 
by extrusion-spheronization had a high drug load of 50% and the pellet core was 
physically separated from the bulk medium during dissolution by the release 
rate controlling EC coat. Therefore, if the initial drug concentration in the core 
is above the drug solubility, the dissolution behavior of such system with a 
spherical shape should ideally follow the zero-order release kinetics. The 
dissolution rate of the drug could be calculated using Eq. (23), which is derived 










*t                                                                                                  (23) 
where dM is the mass transported in the time interval dt, Kd is the diffusion 
coefficient, Kpc is the partition coefficient of the drug within the membrane, Co 
is the solubility of the drug in the core, Ri and Ro are the inner and outer radii 
of the spherical particles, respectively.  
 
The cumulative drug release profiles of ensemble pellets with 8% and 10% coats 
using the dissolution apparatus 1 and 2 are shown in Figure 14 and the modelled 






As can be seen, the two types of pellets exhibited different release patterns and 
rates in the two dissolution apparatus. With the paddle dissolution apparatus, 
the release profile of pellets with 8% coat was observed to follow the zero-order 
model (R2 = 0.990) while that of pellets with 10% coat followed closer to the 
Higuchi model (R2 = 0.991). However, when using the basket dissolution 
apparatus, the dissolution profile of pellets with 8% coat fitted better to the 
Higuchi model (R2 = 0.989) and that of pellets with 10% coat followed closer 


































8 % coat -paddle
8 % coat -basket
10 % coat -paddle
10 % coat -basket
Figure 14. Cumulative drug release profiles of ensemble of extended release 
pellets with 8% and 10% coats using USP dissolution apparatus 1 (basket) and 







Table 9. Coefficients of determination obtained from ensemble of extended release pellets with 8% and 10% coats according to three mathematical 















8 Paddle 0.990 0.253 0.982 5.331 0.726 0.005 26.0 ± 3.5 125.6 ± 4.4 
20 
8 Basket 0.925 0.238 0.989 5.158 0.689 0.004 19.5 ± 3.3 109.0 ± 11.3 
10 Paddle 0.959 0.238 0.991 5.126 0.693 0.005 32.6 ± 2.4 152.8 ± 13.1 
30 
10 Basket 0.990 0.202 0.967 4.223 0.824 0.005 56.8 ± 6.1 225.4 ± 7.5 
K0, K1 and Kh refer to the release kinetic constants obtained from the linear curves of zero-order, first-order and Higuchi models, respectively. 
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More importantly, for both pellet batches with 8% and 10% coats, the values of 
the difference factor f1 were above 15, indicating that their drug release profiles 
obtained from the two dissolution apparatus were significantly different. 
Therefore, the cumulative release profiles of ensemble pellets seemed to be 
confounded when USP dissolution apparatus 1 and 2 were applied for 
differentiating the release properties of the extended release pellets. 
 
For the paddle dissolution apparatus, pellets with 8% coat were observed to float 
on the surface of the dissolution medium throughout the drug release test. T10% 
and T50% values from the drug release profiles were found to be longer than 
those obtained using the basket dissolution apparatus, which suggested a slower 
drug release rate of 8% coat pellets with the paddle apparatus. On the other hand, 
the pellets with 10% coat were found to float initially and then sink into the 
dissolution medium during the drug release test with the paddle dissolution 
apparatus. The shorter T10% and T50% values of the release profile indicated a 
faster drug release rate than that with the basket dissolution apparatus. Floating 
of pellets had significantly reduced the effective surface area in contact with the 
dissolution medium and thus slowed down the drug release rate (Pillay and 
Fassihi, 1998). Moreover, excessive variability in drug release rate has also been 
reported due to the highly heterogeneous fluid flow and complex 
hydrodynamics with the paddle dissolution apparatus (Ameur and Bouzit, 2013). 
The use of a wire or glass helix sinker, attached to the dosage units, to prevent 
them from floating (Nakamichi et al., 2001), could also significantly impede 
drug release and lead to uneven dissolution from the sides of the dosage form 
(Burgess et al., 2004). Therefore, the cumulative release profile of the ensemble 
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pellets obtained by the paddle method may not truly reflect the actual drug 
release mechanism of extended release pellets and may even result in erroneous 
interpretations of the applied pellet coat properties.  
 
With the basket dissolution apparatus, the pellet floating problem was avoided 
by entrapping the pellets in the dissolution basket. However, during the 
dissolution studies, conditions such as the clumping of pellets could occur due 
to limits imposed by the confined space and low shear force in the basket 
(D’Arcy et al., 2006). The cumulative release profile of ensemble pellets with 
8% coat, using the basket apparatus, appeared to have a two-phase release 
profile with a more rapid release initial phase followed by a slower release 
second phase. It was likely that the initial faster release behavior of the extended 
release pellets was the outcome of turbulence among the pellets with propensity 
to float while being confined within the dissolution basket. In the second phase, 
as the tendency for the pellets to float reduced with the imbibed dissolution 
medium, clustering of the pellets may occur at the bottom of the basket, thereby 
limiting the surface area available for the release of drug. These are possible 
explanations for the two-phase release behavior for the pellets with 8% coat 
when drug release test was carried out using the basket dissolution apparatus. 
For pellets with 10% coat, the zero-order drug release rate was obtained as 
possibly, due to their heavier weights with more complete and uniform coating 
on the pellets, the outcome was less buoyant pellets with much reduced 
tendency to float. Thus, the pellets with 10% coat were more easily dispersed in 
the dissolution medium and wetted to form the dissolution barrier capable of 
providing a constant drug diffusion rate. Therefore, in the subsequent studies, 
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the pellets with 10% coat were selected as model pellets for the investigation of 
individual pellet dissolution using the 400-DS dissolution apparatus 7 by the 
DoE approach. 
 
4.2.3 Optimizing operating parameters for dissolution testing of 
individual extended release pellet in the 400-DS dissolution apparatus 7 by 
the DoE approach 
The results of Ravg and Rstd from a total of 17 experiments in the DoE are shown 
in Table 10. The results were analyzed by ANOVA and RSM to determine the 
possible main and interaction effects of design variables on the responses. The 
estimated response surface coefficients and model significance are listed in 
Table 11.  
 
Table 10. Response variables for individual dissolution study of extended 
release pellets in 400-DS dissolution apparatus 7. 
  
Order   Response variables 
Std Run   Ravg Rstd 
1 1  6.47 4.97 
16 2  8.19 3.80 
5 3  10.21 7.22 
6 4  6.91 5.30 
8 5  13.71 8.62 
10 6  12.21 5.83 
7 7  25.83 13.93 
11 8  5.05 2.98 
17 9   9.42 6.66 
13 10   10.88 7.77 
3 11  26.54 14.74 
12 12  12.02 4.93 
14 13   8.70 3.35 
2 14  9.65 7.46 
9 15  6.48 4.17 
15 16  9.07 5.29 
4 17   12.03 6.28 
 108 
 
Table 11. Estimated response surface coefficients and model significance. 
e the term was excluded from the model at α = 0.05 level 
f measures the signal to noise ratio.  A ratio greater than 4 is desirable. 
g implies the chance that a ‘lack of fit’ value could occur due to noise. Non-
significant lack of fit is good as it is desirable for the model to fit. 
 
4.2.3.1 Influence of design variables on the average percentage drug release in 
each dip interval 
The Ravg was found to be between 5.05% and 26.54% (Table 10). A modified 
cubic model (p = 0.000) was successfully developed to describe the relationship 
between the design variables with Ravg and there was insignificant lack of fit of 
the model (p = 0.598). Theoretically, R2 tells how well a model fits the data, 
whereas R2pre reflects how well the model could predict future data. As the R
2 
value always increases when more design variables are added to the model, R2adj 
would be a better estimation of the degree of relationship between design 
variables and responses (Meyers and Montgomery, 2002). As can be seen in 
Table 11, the R2pre (97.50%) and R
2
adj (91.46%) values indicated that the model 
developed for Ravg fitted the data well and was good in its prediction of Ravg. It 
was also found that Ravg was significantly affected by the dip speed (p = 0.000) 
Coefficient Ravg Rstd 
Intercept -92.65 8.63 
Dip speed (A) 8.45 -1.05 
Dip interval (B) 1.09 0.35 
Volume of dissolution medium (C) 9.35 —e 
AB -0.07 -0.01 
AC -0.88 — e 
A2 -0.18 0.04 
A2B 1.22 ×10-3 — e 
A2C 0.02 — e 
Significance of the model developed 0.000 0.003 
R2 (%) 98.75 72.02 
R2pre (%) 97.50 62.70 
R2adj (%) 91.46 49.19 
Adequate precisionf 31.27 10.11 
Lack of fit significanceg 0.60 0.45 
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and dip interval (p = 0.000). Dip speed interacted with dip interval and volume 
of dissolution medium but collectively, they showed a negative effect on the 
Ravg (p < 0.001). The squared term of dip speed was observed to contribute 
negatively to the Ravg (p = 0.000).  The squared term of dip speed was shown to 
interact with dip interval and volume of dissolution medium but contributed 
positively to the Ravg (p < 0.01).  
 
These findings suggested that a higher dip speed would increase Ravg and there 
are synergistic effects with other variables. A higher dip speed of the 
reciprocating holder in the 400-DS dissolution apparatus 7 could contribute to 
stronger hydrodynamic forces in the dissolution medium. The diffusion 
controlled dissolution process could be explained by the commonly used 







*(Cs-Ct)                                                                                                                 (24) 
where dm  is the amount of drug which dissolves in the time interval dt,  S 
denotes the surface area available for drug diffusion, d  is the diffusion 
coefficient of the drug within the unstirred liquid boundary layer,   is the 
thickness of the boundary layer, Cs and Ct are the concentrations of dissolved 
drug at the pellet surface and in the dissolution medium at time t, respectively. 
Nernst-Brunner equation could be used to elaborate the transport of drug 
molecules through the unstirred liquid boundary layer surrounding an extended 
release pellet. During the dissolution study of individual extended release pellet 
using a high dip speed, a more efficient agitation of dissolution medium 
decreased the thickness of the unstirred boundary layer  , through which the 
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drug diffused. The reduced boundary layer thickness consequently resulted in a 
faster drug diffusion rate, or higher  
dm
dt
 . The observed increase in Ravg was likely 
to be due to a more efficient transport of drug molecules between the unstirred 
boundary layer and the well-agitated dissolution medium. The dip interval and 
volume of dissolution medium could also influence 
dm
dt
 by altering ct , the 
concentration of dissolved drug in the dissolution medium at time t. 
 
4.2.3.2 Influence of design variables on the standard deviation of average 
percentage drug release  
The Rstd was found to range from 2.98% to 14.74% (Table 10). As shown in 
Table 11, a significant quadratic model was successfully developed (p = 0.003) 
to describe the effects of design variables on Rstd. The model had relatively poor 
R2pre (62.70%) and R
2
adj (49.19%) values but could still serve to facilitate better 
understanding of the relationship between design variables and Rstd. ANOVA 
revealed that dip speed had a significant negative effect (p = 0.04) on Rstd. The 
squared term of dip speed (p = 0.003) was also observed to be significant, 
suggesting the relationship between dip speed and Rstd was non-linear. A 
reasonably high dip speed generated an unimpeded and constant flow of the 
dissolution medium, which could reduce the unstirred boundary layer to an 
optimal thickness around the pellet during the drug release test. However, if the 
dip speed had been too high, the distribution of shear forces around the unstirred 
layer would likely be non-uniform. Such uneven shear forces might lead to 
heterogeneity in the thickness of the unstirred boundary layer, resulting in 




The positive coefficient (p = 0.053) of dip interval indicated that Rstd increased 
when the dip interval was longer, probably due to the accumulation of dissolved 
drug in the dissolution medium over a longer dip interval. However, if drug 
concentration was excessively high, the presentation of a sink condition in the 
dissolution medium could be impeded, resulting in less consistent drug 
diffusion rate. The dip speed and dip interval were also found to have a 
synergistically negative effect on Rstd (p = 0.018), which revealed that neither 
of these two operating parameters in the 400-DS dissolution apparatus 7 
contributed to the variation in drug release rate of an extended release pellet 
independently.  
 
4.2.4 Optimization of dissolution parameters in the 400-DS dissolution 
apparatus 7 
As the experimental range of Ravg was from 5.05 - 26.54% (Table 10), a medium 
average percentage drug release was chosen and set at 10 - 15%, in order to 
allow for sufficient number of samples in each dissolution test and to avoid too 
fast drug release. For Rstd, the target range was set to a minimum of 3 - 5% to 
reduce the variability in average drug release in each dip interval. Table 12 
shows the results of numerical optimization with highest desirability by the 
numerical optimization function in Design-Expert statistical software. 
Desirability value (D-value) is a measure of the accuracy of prediction. The 
closer the predicted response to the target, the closer the D-value is to one. 
Although five combinations of dependent variables with the highest D-value 
(Number 1-5) were generated by the software, they were very close to each other 
and not the best operating parameters from the technical point of view.  
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Table 12. Results of numerical optimization with the highest D-value and the 
optimized conditions chosen for use in individual dissolution by 400-DS 
dissolution apparatus 7. 
 
 
For instance, it was operationally challenging to set the dip speed of the 
reciprocating holder to exactly 15.53 DPM and the dissolution volume to be 
11.94 mL. Therefore, taking everything into consideration, optimized 
parameters with a slightly lower D-value of 0.984 were chosen (Number 6) to 
confirm the validity of the models generated by RSM.  
 
Triplicated confirmation runs of individual dissolution in 400-DS dissolution 
apparatus 7 under the chosen optimized parameters were conducted. The results 
are summarized in Table 12 and the mean of Ravg and Rstd were compared to the 
predicted response. 95% PI was defined as 95% of prediction interval generated 
from the models developed in the DoE and was used to predict the 95% 
confidence interval of response variable for the next single observation under a 
specific setting of design variables. 95% PI could help to assess the response of 
confirmation experiments where more than one experimental run at the 
optimized settings of design variables were carried out. If the response of 
confirmation experiments were within the 95% PI, then the confirmation would 











Ravg Rstd D-value 
1 15.53 29.37 11.94 10.32 4.97 1 
2 16.23 31.29 11.95 10.06 4.99 1 
3 13.26 23.59 11.45 10.70 4.95 1 
4 15.77 30.02 11.63 10.06 4.98 1 
5 13.35 22.60 11.34 10.10 4.75 1 
6 15 30 12 11.19 5.25 0.984 
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of predicted responses and their standard deviations were rather low, indicating 
that the drug release profiles of individual extended release pellets in the 400-
DS dissolution apparatus 7 could be accurately predicted by the RSM models 
developed in this study. 
 
4.2.5 Comparison of release behaviors between the ensemble pellets and 
individual pellets 
The cumulative release profiles of ensemble pellets were confounded by the 
conditions of pellets during dissolution studies, such as whether they tended to 
float on the surface of the dissolution medium or underwent dissolution as an 
aggregated cluster in the dissolution basket. Hence, the ensemble pellets release 
profile represents both the cumulative release of all the pellets within as well as 
their potential interactive, like aggregation, or non-interactive, like floating, 
tendencies. Thus, the ensemble pellet release may not represent the drug release 
behaviors of individual pellets. The 400-DS dissolution apparatus 7 has a 
variety of custom reciprocating holders, which are readily available to 
accommodate dosage forms of different sizes and shapes. These reciprocating 
sample holders could contain the whole dosage form and agitate according to 
the programmed agitation rate. Such agitation allows the dosage form to move 
freely through the dissolution medium. Hence, the confounding effects by the 
conditions of pellets during dissolution studies were minimized.  
 
The cumulative release profiles of individual extended release pellets with 8% 
and 10% coats are shown in Figure 15. Linear relationships between cumulative 
drug release and dissolution time were obtained for extended release pellets with 
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8% and 10% coats with R2 = 0.991 and 1.000, respectively. The observed 
constant drug release rate supported the zero-order release model of extended 
release pellets with 10% coat using the basket dissolution apparatus. As the 
pellet samples chosen for individual dissolution analysis were consistent in their 
diameters (850 µm sieve aperture size), the effects of pellet size and surface area 
on the dissolution rate were minimized. The higher standard deviation in the 
individual drug release profiles indicated greater differences in the coat quality 
of pellets with 8% coat. Similarly, the significantly lower inter-pellet variability 
in cumulative drug release for extended release pellets with 10% coat also 
suggested a more uniform coat formation with more EC polymer deposited onto 
the pellet surface.  
  
y = 9.485x - 12.999 (R² = 0.991)




































Figure 15. Cumulative drug release profiles of individual extended release 
pellets with 8% (░) and 10% (■) coats and their linear correlation values. 
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This was also corroborated by the coat thickness measurement using SEM, in 
which the RSD of coat thickness for pellets with 10% coat was much lower. 
Therefore, the coat quality of extended release pellets can be distinguished by 
the standard deviations of cumulative drug obtained from individual dissolution 






4.3 Study C. Part 1 - Development of cushioning agents with optimal 
stability and protective effect for compaction of coated pellets  
Cushioning agents are essential in the MUPS formulation to avoid fusion of 
pellets into a non-disintegrating matrix, as well as to minimize the deleterious 
effects of the compaction force on the pellet coat. Ideal cushioning agents 
should possess good compressibility and be capable of forming non-segregating 
uniform blends with the coated pellets. Such blends will be capable of producing 
tablet batches with low weight variation and good content uniformity yet 
mechanically strong at relatively low compression forces and capable of rapid 
disintegration.  
 
Spray dried lactose possesses desirable characteristics for the tableting process, 
such as higher deformability and better interparticulate bonding capacity, 
compared with crystalline lactose (Vromans et al., 1987). Despite its advantage 
for tablet compaction, the instability of amorphous lactose is well known. 
Numerous studies have shown the tendency of amorphous lactose to take up 
moisture upon storage at different RH conditions (Chidavaenzi et al., 1997; 
Chidavaenzi et al., 2001). In the food industry, the presence of amorphous 
lactose has been identified as one of the root causes for the caking of dairy 
powders (Listiohadi et al., 2008). The physical instability of amorphous lactose 
is mainly attributed to the absorbed water acting as a plasticizer to reduce the 
glass transition temperature (Tg). As Tg drops to or below room temperature, 
spontaneous conversion of lactose from amorphous to crystalline state is 
inevitable. Therefore, it is necessary to examine the hygroscopic behavior and 
physical state of amorphous lactose upon storage at different RH conditions.  
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Mannitol, as a non-hygroscopic excipient, is widely used in pharmaceutical 
formulations and with moisture-sensitive ingredients (Naini et al., 1998). It has 
been observed to improve flowability and compactability, and reduce 
hygroscopicity when co-spray dried with acetaminophen (Gonnissen et al., 
2007). Hence, co-spray drying of ML with mannitol could be a potential 
approach to produce cushioning agents that possess both improved 
physicochemical properties and cushioning effects. In this study, composite 
particles containing ML and mannitol were prepared by spray drying. The effect 
of mannitol concentration on the physicochemical properties and stability of co-
spray dried ML and mannitol were evaluated with the spray dried materials 
stored at different RH conditions. Subsequently, ML and the various types of 
spray dried materials were compacted with coated pellets for comparison of 
their cushioning effects.  
 
4.3.1 Physical characterization of spray dried materials 
The physical properties of ML and the various types of spray dried materials 
containing ML and mannitol are summarized in Table 13. As can be seen, the 
moisture contents of all the materials studied were lower than 3.5%. Thus, the 
effect of moisture on any observed difference between the physicochemical 
properties should be minimal, if any. ML was very fine in particle size (2.4 µm) 




















D50 (µm) Span Hausner ratio 
Carr’s index 
(%) 
ML 2.76 ± 0.30 2.4 ± 0.03 2.10 ± 0.01 85.7 ± 2.0 0.185 ± 0.009 0.415 ± 0.006 2.24 ± 0.11 55.42 ± 3.87 
sLac 2.96 ± 0.50 13.9 ± 2.1 2.25 ± 0.09 - - - - - 
sMan 3.02 ± 0.13 11.8 ± 0.6 0.61 ± 0.03 - - - - - 
sML 2.64 ± 0.44 37.0 ± 1.1 2.02 ± 0.02 44.7 ± 3.1 0.311 ± 0.010 0.516 ± 0.013 1.66 ± 0.03 39.78 ± 1.22 
sML_Man1 3.02 ± 0.05 43.3 ± 1.9 1.96 ± 0.01 69.1 ± 1.0 0.232 ± 0.010 0.446 ± 0.017 1.93 ± 0.02 48.07 ± 0.41 
sML_Man2 3.31 ± 0.16 31.2 ± 1.1 2.34 ± 0.01 68.4 ± 2.9 0.231 ± 0.004 0.406 ± 0.012 1.76 ± 0.08 43.10 ± 2.63 
sML_Man4 3.20 ± 0.24 22.8 ± 0.5 2.22 ± 0.02 67.7 ± 3.3 0.213 ± 0.013 0.394 ± 0.009 1.85 ± 0.14 45.84 ± 4.20 
sML_Man2_L 3.12 ± 0.44 46.6 ± 1.7 1.90 ± 0.06 71.4 ± 2.6 0.380 ± 0.011 0.582 ± 0.006 1.53 ± 0.05 34.71 ± 2.32 
* measured as the Day 1 baseline value for the material stability investigation upon storage at different RH conditions  








(A) (B) (C) (D) 
(E) (F) (G) (H) 




The D50 values of sLac and sMan were approximately 13.9 µm and 11.8 µm. 
The spray dried materials containing ML exhibited larger mean particle sizes, 
with the D50 values ranging from 22.8 to 43.3 µm. Interestingly, increasing the 
ratio of dissolved mannitol to lactose in the formulations yielded spray dried 
materials with decreased D50 values. SEM photomicrographs depicting the 
appearances of ML and spray dried materials are given in Figure 16. The sLac 
and sMan exhibited highly spherical shape and smooth surfaces, suggesting a 
rapid and sufficient removal of moisture during the drying process (Walton and 
Mumford, 1999). For the spray dried materials containing ML, the particles 
showed porous structures with an external layer of fine ML particles connected 
together by amorphous lactose. This observation, together with the particle size 
data, confirmed the successful agglomerative size enlargement of ML with 
mannitol by co-spray drying.  
 
Hauser ratio and Carr’s index have been shown to be useful qualitative 
parameters indicating the compressibility of granular materials (Hausner, 1967; 
Abdullah and Geldart, 1999). A higher Hausner ratio corresponds to greater 
inter-particle friction forces. As can be seen in Table 13, ML had the lowest 
bulk density and highest value of both Hauser ratio and Carr’s index. This was 
likely due to the fact that ML had very small particle size and greater number 
of contact points with the neighboring particles, resulting in higher inter-particle 
forces and mechanical interlocking (York, 1978). The higher compressibility of 
ML also suggested that during compaction, ML underwent a longer period of 
particle rearrangement phase before extensive particle deformation took place 
(Huffine and Bonilla, 1962). When employed as the cushioning agent, such 
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property of ML was found to be advantageous in reducing the degree of pellet 
coat damage during compaction (Chin, 2016).  All the three types of co-spray 
dried ML with mannitol exhibited lower bulk density, higher Hauser ratio and 
Carr’s index values compared with sML, suggesting that they were more porous 
and compressible.    
 
The physical states of lactose in the materials were investigated using XRD and 
DSC. As can be seen in the X-ray diffractograms of the materials (Figure 17), 
spray drying of lactose from a saturated solution yielded amorphous lactose due 
to the rapid solidification during the spray drying process (Sebhatu et al., 1994a). 
The diffraction patterns of the ML were very similar to those of the 
recrystallized lactose standard, suggesting that the crystalline structure of 
lactose did not change after micronization. It was previously found that 
diffraction peaks at 10.6° and 12.6° were the signature peaks of crystalline 
lactose β- and α-monohydrate, respectively (Chidavaenzi et al., 2001). 
Therefore, it can be verified that the crystalline form of lactose in the ML and 
spray dried materials were predominantly α-monohydrate. From the calculated 
Cr (%) shown in Table 13, the sML had a significantly lower value of 44.7% 
than those of the co-spray dried ML with different amounts of mannitol, which 
were generally in the range of 60-70%. Thus, all the co-spray dried ML with 
mannitol exhibited higher Cr (%) values than the theoretical Cr (%). The higher 
Cr (%) might be due to the presence of mannitol in the formulation, which 
remained in the crystalline state after being spray dried. This postulation was 
also confirmed by the XRD peaks of sMan at 2θ of 10.47°, 14.56°, 23.45° and 
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29.48°, which have been identified to be the typical and discriminative peaks of 





The DSC thermograms of the lactose containing materials and spray dried 
mannitol are shown in Figure 18. For sLac, the exothermic peak fell in the range 
of 100-120 °C and represented the recrystallization of amorphous lactose, which 
confirmed the amorphous state of lactose. However, the observed lactose 
recrystallization temperature is lower than the reported range of 145 - 170 °C 
for amorphous lactose (Lehto et al., 2006). The lower recrystallization 
temperature could be attributed to the presence of moisture in the prepared 
samples. Amorphous lactose is known to take up moisture rapidly and the 
formation of hydration bonds between lactose and water molecules has been 
known to reduce the recrystallization temperature of amorphous lactose (Haque 









Figure 17.  X-ray diffractograms of (A) sLac; (B) sMan; (C) recrystallized 
lactose; (D) ML; (E) sML; (F) sML_Man1; (G) sML_Man2; (H) sML_Man4 
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and the peak was also seen in the thermogram of sML_Man4, which had the 
highest ratio of mannitol in the formulation.  
 
With regard to the materials containing ML, the peaks at approximately 140 °C 
and 214 °C represented the release of water of hydration and melting of lactose 
α-monohydrate, respectively. It should be noted that for ML, the release of 
water of hydration peak appeared to be much broader than that of the 
recrystallized lactose. This was likely because the size reduction of lactose 
caused the formation of defects and some anisotropic distortions in the crystal 
lattice, and such crystal defects disrupted the intermolecular hydrogen bonds 
between the water and lactose. As a result, a lower dehydration activation 
energy was needed for water molecules to escape from the surface of lactose α-










Figure 18. DSC thermograms of (A) sLac; (B) sMan; (C) recrystallized 




4.3.2 Stability of co-spray dried ML with mannitol upon storage at 
different RH conditions 
The change in moisture content and Cr (%) of the spray dried materials after 
storage in different RH conditions for 14 and 28 days were determined by 
comparing the Day 1 base line values (Table 13) with the Day 14 and Day 28 
data, respectively. For the moisture content after storage shown in Figure 19 (AI 
and AII), amorphous lactose (sLac) took up moisture significantly upon storage 
at 50% RH. When stored at increased RH level of 75%, the moisture contents 
of sLac were found to be 1.05% (Day 14) and 2.61% (Day 28), which were even 
lower than the moisture content of sLac on Day 1. This observation was 
expected as the transition of amorphous lactose to crystalline states released the 
absorbed moisture (Vromans et al., 1987; Sebhatu et al., 1994b), which was also 
confirmed by its increased Cr (%) values as shown in Figure 19 (BI) and (BII). 
For most of the spray dried materials, their moisture contents remained 
relatively unchanged when stored at different RH levels, except for sML_Man1 
which showed a slight increase in moisture content from 3.0% to 5.3% at 75% 
RH. When stored for 28 days (Figure 19 AII), the moisture contents of sML and 
sML_Man_1 increased more than 1% compared with the moisture contents of 
the freshly prepared samples.  
 
With regard to the change in Cr (%) as shown in Figure 19 (BI) and (BII), sLac 
was unstable, with transition from amorphous to crystalline state. The transition 
was initiated at 10% RH and accelerated when RH level was ≥ 50%. After 
storage for 14 days, sML exhibited an increase in Cr (%) from 44.7% (Day 1) 
to 66.5% even at a low RH level of 10%. Increasing the storage RH to 50% led 
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to a further rise in Cr (%) to 85.7%. For co-spray dried materials containing ML 
and mannitol, the Cr (%) was also observed to increase from 60% (Day 1) to 


















































































Figure 19. The (A) moisture content and (B) Cr (%) of spray dried materials 
after storage in different relative humidity conditions for (I) 14 and (II) 28 days, 




Among the three levels of investigated RH conditions, sML and sML_Man1 
exhibited Cr (%) increased at 50% RH, whereas for sML_Man2 and sML_Man4, 
their Cr (%) was observed to increase at 75% RH. It seemed that the addition of 
mannitol in the formulation facilitated enhancement of the stability of sML at 
elevated RH. After storage for 28 days at 50% RH, the Cr (%) of sLac increased 
from 23.5% (Day 14) to 50% (Day 28), while the Cr (%) for all the spray dried 
materials remained more or less similar to their Cr (%) measured on Day 14.  
 
4.3.3 Cushioning effects of co-spray dried ML with mannitol 
Co-spray drying of ML with mannitol should ideally yield materials that possess 
improved physicochemical properties compared with ML, while maintaining or 
increasing its cushioning effects for aiding in the compaction of coated pellets. 
MUPS tablets were prepared with EC-coated pellets using ML and various 
spray dried materials as cushioning agents in a ratio of 1:1 (w:w), at compaction 
pressures of 43 MPa and 60 MPa. ML was chosen as a positive control for the 
comparison of cushioning effects. Table 14 summarizes the tensile strength, 
disintegration time and MDT of the MUPS tablets prepared. The tablets 
comprising ML and EC-coated pellets were generally very soft and tablet 
capping and lamination were observed. At compaction pressure of 40 MPa, the 
tensile strength of the resultant tablets was too low to be measured. This was 
due to the weak interparticulate bonds between the crystalline ML particles and 








Table 14. Tensile strength, disintegration time and MDT of MUPS tablets prepared with EC-coated pellets using ML and spray dried materials as 
cushioning agents at two levels of compaction pressure. 
 
     Tablet Code 












T_ML 0 < 10 s 20.9 ± 1.6 0.05 ± 0.01 16 ± 2 14.9 ± 1.4 
T_sML 0.59 ± 0.05 61 ± 5 20.0 ± 1.0 0.85 ± 0.04 153 ± 15 17.0 ± 1.2 
T_sML_Man1 0.33 ± 0.01 26 ± 2 26.4 ± 1.6 0.75 ± 0.07 41 ± 5 18.3 ± 0.8 
T_sML_Man2 0.39 ± 0.03 25 ± 2 26.4 ± 1.9 0.76 ± 0.07 37 ± 7 17.8 ± 1.0 
T_sML_Man4 0.59 ± 0.07 26 ± 6 18.9 ± 0.6 0.89 ± 0.04 45 ± 4 14.9 ± 0.5 
MDT: mean dissolution time 
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The MDT of EC-coated pellets before compaction was found to be 94.6 ± 1.9 
min whereas the MDT of T_ML tablets was much lower (20.9 ± 1.6 min) at 
compaction pressure of 40 MPa. Hence, ML did not seem to confer sufficient 
protective effect to the EC-coated pellets during compaction. This may be 
because ML did not form a homogeneous cushioning layer around the EC-
coated pellets to absorb the applied compaction energy due to segregation. All 
the MUPS tablets were observed to disintegrate within 60 seconds, except for 
the T_sML tablets containing sML and EC-coated pellets. At the compaction 
pressure of 40 MPa, the ranking of tensile strength for the MUPS tablets 
containing different cushioning agents was: T_sML_Man4 ≈ T_sML > 
T_sML_Man2 > T_sML_Man1 > T_ML. The order of MDT for MUPS tablets 
with different cushioning agents showed a reversed trend when compared to the 
tablet tensile strength trend, which was T_sML_Man1 ≈ T_sML_Man2 > 
T_ML > T_sML > T_sML_Man4. The cushioning effects of all the spray dried 
materials were compared against that of ML using the similarity factor f2 to 
indicate whether the dissolution profiles are statistically different. As can be 
seen in Table 15, the f2 values of MUPS tablets using sML-Man1 and 
sML_Man2 as cushioning agents were closest to 50. This indicated that 
sML_Man1 and sML_Man2 had superior cushioning effects compared with ML. 
The co-spray dried ML with mannitol could have unique porous structures 
containing fine ML particles on the surface. Upon compaction, internal collapse 
of these particles took place and the primary ML particles on the surface re-
arranged themselves to conform to the shape of the EC-coated pellets. Thus, the 




However, when a higher compaction pressure of 63 MPa was employed, all the 
MUPS tablets had equivalent dissolution profiles with all the f2 values higher 
than 50. This observation indicated that the EC-coated pellets were damaged 
and lost their coat functionality regardless of the cushioning agents used due to 
extensive pellet crack formation and coat breakage when the compaction 
pressure was too high.  
 
Table 15. The similarity factor f2 values of MUPS tablets using different spray 
dried materials as cushioning agents (calculated based on the reference 
dissolution profile of MUPS tablets containing ML as cushioning agent). 
 
A cushioning agent prepared by co-spray drying of ML and mannitol for 
compaction of EC-coated pellets should ideally possess the following properties: 
firstly, stability upon storage at elevated RH, including minimal changes in the 
moisture content and Cr (%). Secondly, the dissolution profile of the resultant 
MUPS tablets should be as close to that of the uncompacted pellets as possible. 
Last but not least, the particle size of the cushioning agents should be large 
enough to allow for a more homogeneous blend with the EC-coated pellets. 
From the discussion above, it is clear that the all the co-spray dried materials 
exhibited better physicochemical properties than ML. It was also found that 
mannitol had a positive effect on increasing the stability of lactose upon storage 
at high moisture environment. In addition, MUPS tablets formed using co-spray 





T_sML T_sML_Man1 T_sML_Man2 T_sML_Man4 
 f2 
40 74.2 ± 9.8 50.6 ± 5.3 51.7 ± 5.6 67.2 ± 7.1 
63 73.3 ± 8.7 74.1 ± 9.2 76.5 ± 8.5 62.0 ± 6.8 
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disintegration time. Among the co-spray dried materials containing ML and the 
three different ratios of mannitol, the use of sML_Man2 conferred superior 
cushioning effect to EC-coated pellets and formed relatively strong MUPS 
tablets. Therefore, 2%, w/w mannitol, corresponding to the ratio of dissolved 
lactose and mannitol 10:1 (w:w), was considered as the optimal concentration 
among the investigated co-spray dried ML and mannitol formulations.  
 
In order to increase the size of spray dried particles, a rotary atomizer was 
employed during the spray drying process. From Table 13, it can be seen that 
the sML_Man2_L produced using the rotary atomizer exhibited larger particles 
size (46.6 µm) and retained the porous structure (Figure 16-H), compared with 
sML_Man2 (31.2 µm) that was produced using the two fluid spray nozzle. 
Therefore, sML_Man2_L was employed as the cushioning agent for 
investigating the formulation and process strategies to minimize coat damage 
for compaction of EC-coated pellets in a rotary tablet press. 
 
4.4 Study C. Part 2 - A mechanistic approach for analyzing the pellet 
coat damage caused by compaction in a rotary tablet press  
To date, most of the studies that investigated pellet coat damage caused by 
compaction were conducted using an eccentric single punch tablet press or a 
compaction simulator. The knowledge obtained from such studies might not be 
directly translated to the rotary tableting process, due not only to the material 
feeding process but also to differences in their modes of force application and 
compaction mechanism. The primary aim of this part of the study was to 
investigate, via a mechanistic approach, formulation and process strategies to 
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minimize pellet coat damage during compaction in a rotary tablet press. Two 
compaction process parameters, dwell time and applied pressure, were 
examined for their effects on the physicomechanical properties of resultant 
MUPS tablets and the extent of damage to the EC coats on the pellets. In order 
to elucidate the extent and mechanism of coat damage caused by compaction, 
the crushing strength of the EC-coated pellets and degree of coat damage of 
excavated individual pellets from different locations in the MUPS tablets were 
investigated. In addition, changes in pellet volume fraction in MUPS tablets 
under different compaction pressures and with different sML_Man2_L:pellet 
ratios were examined and correlated with the extent of pellet coat damage. 
4.4.1 Effect of dwell time and compaction pressure on the physicomechanical 
properties of MUPS tablets 
The thickness, tensile strength and MDT of MUPS tablets compacted at 20, 30 
and 40 MPa, with increasing dwell times of 10, 25 and 40 ms are shown in 
Figure 20. As can be seen in Figure 20 (A) and (B), a higher compaction 
pressure produced thinner but stronger tablets, regardless of the dwell time used. 
This trend was expected, as increasing the compaction pressure led to more 
energy being transmitted to the powder bed during the compaction process and 
had allowed more interparticulate bond formation. At the same level of 
compaction pressure, tablet thickness decreased while tensile strength increased 
with extended dwell time from 10 to 40 ms. For instance, at 40 MPa, the tensile 
strength of MUPS tablets compacted with dwell time of 40 ms was 62.8% 































































































Figure 20. The (A) thickness, (B) tensile strength and (C) MDT of MUPS 
tablets prepared at compaction pressure of 20, 30 and 40 MPa with dwell time 
of 10 ms (■), 25 ms (□) and 40 ms (░). 
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 Dwell time is defined as the interval during which maximum compaction 
pressure (defined as > 90% of peak pressure) is maintained by the punches 
during the compaction cycle (Vezin et al., 1983). It has been shown that an 
extended dwell time is more beneficial for predominantly plastically deforming 
material which undergoes time dependent deformation as a longer 
interparticulate contact time allows for more extensive plastic deformation and 
greater bond formation (Akande et al., 1997). From the analysis of Heckel plots 
(Figure 21), it was observed that both the sML_Man2_L and EC-coated pellets 
exhibited certain degrees of plastic deformation behavior, with yield pressures 
of 72 and 107 MPa, respectively. Therefore, the longer dwell time had enabled 
more extensive interparticulate bond formation under compaction, resulting in 



















Figure 21. Heckel plot of sML_Man2_L (●) and EC-coated pellets (□). 
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Disintegration times of the MUPS tablets prepared were generally less than a 
minute and drug release rate would unlikely be severely impacted by any 
prolonged disintegration of the MUPS tablets. The dissolution profiles of the 
uncompacted pellets and MUPS tablets compacted at 20, 30 and 40 MPa, with 
increasing dwell times of 10, 25 and 40 ms are plotted in Figure 22. Generally, 
all the MUPS tablets exhibited faster drug release rate compared with the 
uncompacted pellets. It was also observed that the MUPS tablets prepared using 
a lower compaction pressure had relatively slower drug release rate, indicating 
a reduced extent of pellet coat damage, in comparison with those prepared at 
higher compaction pressures. The MDT of all the MUPS tablet samples are 
shown in Figure 20 (C). Although extending the dwell time during compaction 
was found to significantly increase the tensile strength of MUPS tablets, it 
apparently did not affect the MDT of MUPS tablets, when compacted using the 
same pressure. This suggested that the pellet coat damage was not exacerbated 
by the duration of force application during the tableting process. On the other 
hand, increasing the compaction pressure from 20 to 40 MPa led to a drastic 
decrease in the MDT of the resultant MUPS tablets, from 40 to 20 min. This 
observation indicated that for the compaction of EC-coated pellets, the coat 
damage sustained was more sensitive to the magnitude of the compaction 
pressure than to the duration of force application. This postulation was also 
supported by the study of Çelik and Maganti (1994) where microspheres coated 
with EC were found to lose their release rate controlling properties, regardless 
of the coat thickness and rate of force application. Although a low compaction 
force is desirable to minimize the extent of pellet coat damage when preparing 
MUPS tablets, the mechanical strength of the MUPS tablets produced must be 
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adequate for surviving the normal hazards of post-compaction handling. 
Therefore, the application of extended dwell time during tableting would 
facilitate the formation of stronger tablets without causing further damage to the 
















































Figure 22. Dissolution profiles of the uncompacted pellets and MUPS tablets compacted using different compaction pressures and 
dwell times.  
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4.4.2 Compaction pressure and pellet coat damage 
The physical and mechanical properties of the drug-loaded pellets and EC-
coated pellets are shown in Table 16. Both these two types of pellets were of 
about 600 μm in diameters, highly spherical and had roundness values of about 
1.1. The crushing strengths of the drug-loaded and EC-coated pellets were 13.5 
and 14.7 MPa, respectively. The increase in crushing strength after application 
of the EC coat indicated a small increased of the mechanical strength of the 
drug-loaded pellets after the application of an additional polymeric film over-
coat layer (Maganti and Çelik, 1994).  
 
A close examination of the EC-coated pellets located at the tablet axial 
peripheral surface can be made from the SEM photomicrographs of MUPS 
tablets compacted at 13, 20, 30 and 40 MPa (Figure 23). The EC coat ruptured 
when compacted using pressure higher than the pellet crushing strength (14.7 
MPa) whereas the coat only deformed when the compaction pressure employed 
was slightly lower than 14.7 MPa. During compaction in a rotary tablet press, 
the powder bed densification process is biaxial as both the upper and lower 
punches pass between the compression rolls (Picker-Freyer, 2008). Therefore, 
a summative compaction force exerted by both punches was applied on the 
peripheral particles and transmitted axially, inwards, into the compact interior. 
As a result, the surface particles were compacted axially and dragged along the 
die wall surface during compaction. When the applied force exceeds the 
minimum force required for particle deformation, the consolidation of particles 




Table 16. The size, shape, average coat thickness and mechanical properties of 
drug-loaded pellets and EC-coated pellets. 
 
















Drug-loaded pellets 589 ± 30 1.12 ± 0.05 81.21 ± 4.52 3.70 ± 0.41 13.5 
EC-coated pellets 604 ± 28 1.11 ± 0.01 8.62 ± 0.67 4.16 ± 0.37 14.7 
(A) (B) 
(C) (D) 
Figure 23. SEM photomicrographs of axial peripheral surfaces of MUPS tablets 
compacted at (A) 40 MPa, (B) 30 MPa, (C) 20 MPa and (D) 13 MPa. 
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Hence, the pellets at the tablet axial and radial peripheral surfaces were more 
liable to be damaged by the applied force due to the extreme shear at these 
surface locations (Frenning, 2007). However, the compaction pressure may not 
be transmitted uniformly to the particles in the central region of the MUPS tablet. 
This could be due to the inherent adhesion of the particles to the wall, causing 
some differential movements of particles. Hence, the extent of damage to the 
EC-coated pellets within a MUPS tablet could be different, depending on their 
spatial position in the tablet.  
 
4.4.3 Location of pellets in a MUPS tablet and extent of coat damage 
Hosseini et al. (2013) examined the dissolution profiles of individual EC-coated 
pellets after compaction at different pressures. The investigators found that 
rupture of the EC coats of the pellets corresponded to a marked increase in the 
drug release rate and only the external cushioning layer of pellets did not show 
significant changes. Therefore, in the present study, the extent of coat damage 
in terms of drug release from individual pellets, defined as the pellet coat 
damage index, was determined to classify the excavated pellets into three 
categories, namely pellets with broken, deformed or intact coats.  
 
As the crushing strength of EC-coated pellets was 14.7 MPa, two levels of 
compaction pressure, 13 and 20 MPa, were chosen to prepare the MUPS tablets. 
Subsequently, the coat damage in pellets located at different positions in a 
MUPS tablet was examined and compared. Percentages of EC-coated pellets 
excavated from MUPS tablets with broken, deformed or intact coats are 



















Compaction pressure  
Location of excavated pellets in the 
MUPS tablets 
(n=100) 
Excavated EC-coated pellets with: 
Broken coat (%) Deformed coat (%) Intact coat (%) 
13 MPa 
Axial peripheral surfaces 38 30 32 
Core region 40 36 24 
Radial peripheral surfaces 42 24 34 
20 MPa 
Axial peripheral surfaces 58 22 20 
Core region 57 24 19 
Radial peripheral surfaces 51 25 24 




When the compaction pressure employed was reduced from 20 to 13 MPa, the 
percentage of pellets with broken coats decreased significantly, regardless of 
the pellets’ position within the tablet. Moreover, there was an increase in the 
percentage of pellets with intact coats, especially for those located at the tablet 
axial and radial peripheral surfaces. This trend was expected as the EC coat was 
more likely to withstand the stress caused by a compaction pressure that was 
lower than its crushing strength. However, for pellets located at the axial 
peripheral surface and core of the MUPS tablets, the percentage of pellets with 
deformed coat was higher at the lower compaction pressure. This might be 
attributed to the damage from pellet-pellet contacts when the areas surrounding 
the coated pellets were not fully encased by the cushioning agent. It has been 
reported that a sufficient proportion of the cushioning agent was necessary to 
form a percolated network of deformable materials to prevent excessive direct 
contact between pellets and punch/die-wall surfaces as well as pellet-pellet 
contacts (Torrado and Augsburger, 1994; Wagner et al., 2000; Dashevsky et al., 
2004). This postulation could also be confirmed by the sample SEM 
photomicrographs showing excavated pellets from the axial and radial 
peripheral surfaces and core of the MUPS tablet (Figure 24). For the pellets 
excavated from MUPS tablets that were prepared at compaction pressure of 20 
MPa, they generally exhibited a higher degree of damage. However, even for 
the pellets from tablets that were prepared using the lower compaction pressure 
of 13 MPa, it was not uncommon to find some surface deformations, especially 
on those excavated from the peripheral surfaces as the deformations may be due 







(I) (II) (III) 
(B) 
(A) 
Figure 24. SEM photomicrographs showing the excavated pellets from the (I) core, (II) axial peripheral surfaces and (III) 
radial peripheral surfaces of MUPS tablets prepared at compaction pressures of (A) 20 MPa and (B) 13 MPa, respectively. 
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When compaction pressure is exerted by the punches onto the powder bed in 
the die, the components generally respond by undergoing volume reduction 
(Çelik and Marshall, 1989). However, for MUPS formulations containing 
different proportions of coated pellets and cushioning agent, the densification 
of these two components would differ due to their differences in compressibility 
and density. Kühl and Mielck (2002) developed a two compartment model to 
detect and quantify the occurrence of deformation of pellets under compaction, 
where the coated pellets and cushioning agent were regarded as non-deforming 
and deforming compartments of the matrix, respectively. For the pellets to 
remain at a nearly constant volume under compaction, the die volume needs to 
be sufficient to accommodate the pellets in a cubic arrangement, with the 
deforming compartment filling up the inter-pellet spaces. Therefore, the actual 
volume of coated pellets in proportion to the tablet matrix, which indicates the 
degree of densification, should be evaluated as an important factor that 
contributes to the extent of pellet coat damage.  
 
4.4.4  Pellet volume fraction and pellet coat damage 
The pellet volume fractions of the tablets formed at compaction pressures of 13, 
20, 30 and 40 MPa, as well as with different ratios of sML_Man2_L to EC-
coated pellets at the lowest compaction pressure (13 MPa) were calculated, in 
order to understand their influence on the extent of pellet coat damage. The 
MDT values were then plotted against the pellet volume fraction (Figure 25). A 
critical pellet volume fraction (CPVF) of 0.374 could be clearly identified from 
the plot and beyond this critical point, there was a drastic decrease in MDT. This 
CPVF was reached when the MUPS tablets containing equal amounts of EC-
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coated pellets and sML_Man2_L by weight were compacted at 13 MPa. The 
pellet volume fraction, f2 value and tensile strength of MUPS tablets formed at 
compaction pressure of 13 MPa with increasing ratios of sML_Man2_L and 
EC-coated pellets are summarized in Table 18. Even at a rather low compaction 
pressure, compacts with pellet volume fractions of 0.374, 0.288 and 0.212 still 
produced dissolution profiles that were significantly different from that of the 
uncompacted pellets (f2 < 50). The coat damage could only be fully mitigated 
at a low pellet volume fraction of 0.137, which incidentally was lower than the 

























Figure 25. Plot of MDT against pellet volume fraction of MUPS tablets. 
 145 
 
Table 18. The pellet volume fraction, f2 value and tensile strength of MUPS 




The CPVF observed in this study was corroborated by the findings of Chin et 
al. (2016) where MUPS tablet formulations containing lactose particles of 
various size and size distributions were employed. The mechanism through 
which CPVF affects pellet coat damage during compaction could be explained 
by the percolation theory. A percolation system consists of sites in an infinitely 
large lattice. As each site in the lattice is occupied randomly, they could form 
loose clusters independent of their neighbors. When these occupied sites come 
into contact with one another continuously, they could span the entire length, 
width and height of the system. The condition or concentration at which a 
percolating or continuous cluster is first formed is known as the percolation 
threshold. In the current MUPS tablet, the CPVF was likely to be correlated 
with the threshold for the formation of a percolating network of cushioning 
particles (Holman, 1991). Theoretically, the volume fraction of pellets should 
be less than 0.3116, which is the fraction of spheres in a simple cubic lattice 
(Stauﬀer and Aharony, 1992). From the Heckel plots of components, 
sML_Man2_L and EC-coated pellets (Figure 21), the deformation of sML-





1:1 3:2 7:3 4:1 
Pellet volume 
fraction 
0.374 0.288 0.212 0.137 
f2 value 34.4 ± 2.0 37.5 ± 2.6 44.9 ± 3.2 52.3 ± 3.2 
Tablet tensile 
strength (N·mm-2) 
0.12 ± 0.02 0.15 ± 0.03 0.20 ± 0.01 0.19 ± 0.01 
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the EC-coated pellets (14 MPa). Therefore, even at a compaction pressure lower 
than 14 MPa, sML_Man2_L particles could undergo rearrangement and plastic 
deformation. Thus, the sML_Man2_L absorbed much of the compressive forces 
by deformation and not only being sacrificial to prevent damage to the EC-
coated pellets, it also enabled the formation of a coherent compact. However, if 
the EC-coated pellets could not be accommodated within the percolating 
network formed by the cushioning agent, the pellets were likely to be subjected 
to high compressive forces more directly, resulting in deformations or even 
damage due to pellet-pellet collisions or pellet impingements onto die or punch 
surfaces caused by the high rate of force application during tableting. This 
postulation was also supported by the examination of the degree of coat damage 
suffered by the individual EC-coated pellets which were excavated from the 
MUPS tablets. When the pellet volume fraction of the MUPS tablets increased 
beyond the CPVF, the excavated pellets showed more extensive degree of 
deformation and fracture despite the presence of ample cushioning particles. 
The reason why the pellets could no longer be cushioned was likely to be due 
to the onset of lateral stress transmission to the die walls (Leuenberger et al., 
1992).  
 
It should also be noted that for this study, a very challenging delivery system 
was adopted, comprising relatively small, mechanically weak sugar cores (355-
425 μm) coated with a brittle EC coat of around 8.6 μm thick and encapsulating 
a highly soluble drug (aqueous solubility of metformin hydrochloride is 
approximately 300 mg/mL). Hence, the coated pellets, especially those located 
at the peripheral tablet surfaces, could easily be damaged when subjected to the 
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rapidly applied compaction forces. In order to minimize pellet-pellet contact 
and contact between pellets and the die wall/punch surface during tableting, the 
ratio of cushioning agent and coated pellets should be adequately increased. 
Thus, this study provided the basis why a pellet volume fraction of 0.137 was 























Chapter 5. Conclusion 
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Study A explored the feasibility of coating irregular-shaped small particles with 
wide size distribution using the FS processor and evaluated the coated particles 
for their coat uniformity and taste masking efficiency. The FS processor was 
found to be a promising technology for direct coating of irregular-shaped 
particles with minimal agglomeration. Although particles larger than 355 µm in 
size were generally under coated due to poorer fluidization during the FS 
coating operation, the taste masking coat was found to be more uniform by 
increasing coat deposition from 5% to 20%, w/w. A 15% coat weight gain was 
observed to have optimal taste masking efficiency, providing sufficient sealant 
properties at salivary pH with subsequent fast dissolution at gastric pH. Such 
optimally taste masked particles could be useful for applications such as in ODT 
platforms.  
 
In study B, a systematic DoE approach was used to optimize the operating 
parameters of the 400-DS dissolution apparatus 7. Mathematical models were 
successfully developed to describe the relationships between design variables 
and responses. The dip speed and dip interval of the reciprocating holder were 
found to be critical parameters that affected the drug release rate of extended 
release pellets by changing the hydrodynamics and sink conditions in the 
dissolution medium. Individual pellet dissolution investigations on the extended 
release pellets in dissolution apparatus 7 were conducted using the optimized 
parameters and the drug release profile from the individual pellet were 
compared with their ensemble release profile. When using the USP dissolution 
apparatus 1 and 2, pellet floating and clumping were observed during 
dissolution and the resultant ensemble release profiles were confounded. On the 
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other hand, the drug release mechanism of extended release pellets could be 
elaborated by the cumulative release profile of individual pellets and the 
standard deviation of drug release rate was a useful coat quality indicator of the 
batch of extended release pellets. The study demonstrated that individual pellet 
dissolution testing using dissolution apparatus 7 was a promising technique for 
evaluating pellet coat quality and for providing better understanding of the 
actual drug release mechanism of a batch of extended release pellets. 
 
In Study C, mannitol was co-spray dried with micronized lactose to prepare 
cushioning agents with enhanced physicochemical properties and protective 
effects for minimizing pellet coat damage during compaction. The addition of 
mannitol also improved the physical stability of spray dried lactose upon storage 
at different RH conditions. MUPS tablet formulations comprising EC-coated 
pellets and the optimized cushioning agent (sML_Man2_L) were prepared 
using a rotary tablet press. The physicomechanical properties of the resultant 
MUPS tablets were investigated. A mechanistic approach was employed to 
analyze individual pellets from different locations in the MUPS tablets. With 
respect to process strategies for minimizing pellet coat damage, an extended 
dwell time employed during tableting was found to significantly improve the 
mechanical strength of the MUPS tablets. When the same compaction pressure 
was applied with different dwell times to prepare MUPS tablets, the MDT of 
the resultant tablets remained unaffected. These two findings suggested that an 
extended dwell time produced stronger MUPS tablets without exacerbating the 
extent of pellet coat damage sustained. However, increasing the compaction 
pressure drastically decreased the MDT of the MUPS tablets. This sensitivity to 
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the magnitude of compaction pressure could be correlated to the intrinsic 
crushing strength of the EC-coated pellets. It was observed that when the 
applied compaction pressure was higher than the pellet crushing strength (14.7 
MPa), the EC coats ruptured whereas the coats were mainly intact, merely 
deformed when the compaction pressure applied was lower than 14.7 MPa. 
Besides the compaction pressure used to form the MUPS tablets, the location of 
the coated pellets within the MUPS tablet could also affect the extent of their 
coat damage, possibly due to the unequal force distribution in the compact 
during tableting. With regard to formulation strategies, the formation of a 
continuous percolating network of cushioning agent is critical to limit the extent 
of pellet-pellet contacts and collisions between pellets and punch/die-wall 
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